Page last updated: 2024-12-05

nad

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15938971
CHEBI ID57540
MeSH IDM0014403
PubMed CID5892
CHEMBL ID1234613
CHEBI ID44215
SCHEMBL ID131544
MeSH IDM0014403

Synonyms (151)

Synonym
nicotinamide-adenine dinucleotide
NCHEMBIO867-COMP14 ,
nad-ox
nicotinamide adenine dinucleotide
dpn-ox
dpn+
diphosphopyridine nucleotide
nad ,
53-84-9
coenzyme i
beta-nicotinamide adenine dinucleotide
adenosine 5'-{3-[1-(3-carbamoylpyridinio)-1,4-anhydro-d-ribitol-5-yl] diphosphate}
CHEBI:57540
nad anion
nad(1-)
3B78
2ZIT
3B8H
Q28529711
76961-04-1
DTXSID201016357
adenosine 5'-(trihydrogen diphosphate), p'-->5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, inner salt, ion(1-)
CHEMBL1234613
nicotinamide adinine dinucleotide
codehydrogenase
nadidum
gtpl2451
beta-nad
co-1
nsc-20272
.beta.-nad
cozymase
nsc20272
endopride
[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] [(2r,3s,4r,5r)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
[(3s,2r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3s,2r,4r,5r)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl)hydrogen phosphate
adenosine 5'-(trihydrogen diphosphate), p'-5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium hydroxide, inner salt
nicotinamide dinucleotide
nsc 20272
nadida [inn-spanish]
nadide [usan:inn:ban:jan]
brn 3584133
adenosine 5'-(trihydrogen diphosphate), p'-5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, inner salt
nicotineamide adenine dinucleotide
pyridinium, 3-carbamoyl-1-beta-d-ribofuranosyl-, hydroxide, 5'-ester with adenosine 5'-5'-(trihydrogen pyrophosphate), inner salt
nadidum [inn-latin]
einecs 200-184-4
adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, hydroxide, inner salt
NCGC00016240-01
cas-53-84-9
NCGC00178839-01
NCGC00178839-02
pyridinium, 3-carbamoyl-1-b-d-ribofuranosyl-, hydroxide, 5'-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), inner salt (8ci)
cozymase i
[32p] nad+
[adenylate-32-p]-nad+
pyridine, nucleotide diphosphate
3-carbamoyl-1-beta-d-ribofuranosylpyridinium hydroxide, 5'-ester with adenosine 5'-pyrophosphate, inner salt
adenine-nicotinamide dinucleotide
beta-diphosphopyridine nucleotide
adenosine 5'-(trihydrogen diphosphate-p-32p), p'>5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, inner salt (9ci)
enzopride
[14c] nad+
codehydrogenase i
codehydrase i
co-i
carbonyl [14c] nad+
beta-dpn
AB00513910
beta-nad+
nad+
nadide
beta-nicotinamide adenine dinucleotide hydrate, >=98%, bioultra, from yeast
beta-nicotinamide adenine dinucleotide hydrate, >=96.5% (hplc), >=96.5% (spectrophotometric assay), from yeast
beta-nicotinamide adenine dinucleotide hydrate, cell culture tested, >=96.5% (hplc), >=96.5% (spectrophotometric assay), from yeast
beta-nicotinamide adenine dinucleotide hydrate, grade aa-1, >=95% (hplc)
beta-nicotinamide adenine dinucleotide hydrate, >=99%
beta-nicotinamide adenine dinucleotide hydrate, purified by column chromatography, >=99%
nad zwitterion
CHEBI:44215 ,
SPECTRUM1500419
beta-nicotinamide adenine dinucleotide, pkg of 50 mg (per vial)
beta-nicotinamide adenine dinucleotide hydrate, >=95% (hplc)
beta-nicotinamide adenine dinucleotide, pkg of 10 mg (per vial)
beta-nicotinamide adenine dinucleotide, reduced
F45C0D6C-DA87-47BE-9975-7A5DE9CCB985
HMS2091H06
D0919
HMS500J11
nad+, free acid
[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
HMS2097E04
pharmakon1600-01500419
nsc-757121
nsc757121
dtxsid2045236 ,
tox21_110321
dtxcid0025236
64417-72-7
CCG-40114
unii-0u46u6e8uk
adenosine 5'-(trihydrogen diphosphate), p'.fwdarw.5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, inner salt
ec 200-184-4
nadida
adenosine 5'-(trihydrogen diphosphate), p'->5'-ester with 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium, inner salt
0u46u6e8uk ,
5-26-16-00399 (beilstein handbook reference)
AKOS015892319
S2518
HY-B0445
SCHEMBL131544
beta-nicotinamide adenine dinucleotide trihydrate
.beta.-nicotinamide adenine dinucleotide
AB00052048_03
mfcd00036253
bdbm213227
nicotinamide adenine dinucleotide (nad)
b-nad
b-dpn
b-nicotinamide adenine dinucleotide
nad, grade ii, free acid
beta-nicotinamide adenine dinucleotide hydrate, vetec(tm) reagent grade, >=96.5%
beta-nicotinamide adenine dinucleotide, pkg of 20 mg (per vial)
beta-nicotinamide adenine dinucleotide hydrate, suitable for manufacturing of diagnostic kits and reagents
nad, grade i, free acid
SBI-0051451.P003
HMS3714E04
pyridine nucleotide diphosphate
[(3s,2r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3s,2r,4r,5r)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl) hydrogen phosphate
3-carbamoyl-1-d-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate
3-carbamoyl-1-beta-d-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt
3-carbamoyl-1-beta-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt
nad trihydrate
3-carbamoyl-1-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate
[adenylate-32-p]-nad
beta-diphosphopyridinenucleotide
1-((2r,3r,4s,5r)-5-((((((((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-carbamoylpyridin-1-ium
|a-dpn; |a-nad; coenzyme 1; nadide
NCGC00178839-03
DB14128
beta-nicotinamide adenine din-ucleotide
AS-14652
nad lithium salt
Q12499775
NCGC00178839-08
nadlithiumsalt
-dpn;-nad;-nicotinamide adenine dinucleotide
EX-A3535
1-[(2r,3r,4s,5r)-5-{[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]methyl}-3,4-dihydroxyoxolan-2-yl]-3-carbamoyl-1-pyridin-1-ylium
AC-37031
BP-58726

Research Excerpts

Overview

CNAD acts as a general dehydrogenase inhibitor but shows unusual specificity and affinity for liver alcohol dehydrogen enzyme (ADH)

ExcerptReferenceRelevance
"CNAD acts as a general dehydrogenase inhibitor but shows unusual specificity and affinity for liver alcohol dehydrogenase (ADH, EC 1.1.1.1)."( CNAD: a potent and specific inhibitor of alcohol dehydrogenase.
Bell, JE; Goldstein, BM; Jones, JP; Li, H; Pankiewicz, KW; Watanabe, KA; Zeidler, J, 1994
)
1.82

Toxicity

The toxic electrophile produced by cytochrome P-450 oxidation of acetaminophen, N-acetyl-p-benzoquinoneimine, is reduced rapidly by NADH in aqueous solution. The induction of cellular NAD(+) levels using dunnione, which targets intracellular NQO1, prevents the toxic effects of cisplatin.

ExcerptReferenceRelevance
" Because redox cycling requires reducing equivalents, we investigated whether ethanol, which generates NADH via alcohol dehydrogenase, would increase hepatotoxicity due to concentrations of adriamycin which by themselves were not toxic in perfused rat liver."( Potentiation of adriamycin toxicity by ethanol in perfused rat liver.
Liu, Y; Thurman, RG, 1992
)
0.28
" The enzymes involved in the toxic metabolic pathway have been investigated in this study."( Rat liver metabolism and toxicity of 2,2,2-trifluoroethanol.
Dunbar, D; Fraser, JM; Kaminsky, LS; Seaman, M, 1992
)
0.28
" The results showed that the carboxylic-containing drugs and the 1,4-dihydroxy AQ were weak sister chromatid exchange inducers and the most toxic among the six anthraquinones examined."( Superoxide anion production and toxicity in V79 cells of six hydroxy-anthraquinones.
Benetti, D; Fratta, D; Gervasi, PG; Mariani, T; Mian, M; Rainaldi, G; Simi, S,
)
0.13
" Further experiments showed that NADH was toxic at the levels used to generate the active species (500 microM)."( Cytotoxicity and activation of CB1954 in a human tumour cell line.
Baer, J; Bagshawe, KD; Sunters, A, 1991
)
0.28
"Human epidermal keratinocytes in culture were studied to evaluate their usefulness in demonstrating toxic events following exposure to sulfur mustard."( The use of human epidermal keratinocytes in culture as a model for studying the biochemical mechanisms of sulfur mustard toxicity.
Chan, P; Gross, CL; Meier, HL; Smith, WJ, 1990
)
0.28
" The severity of the muscle damage induced by these compounds in vivo was found to be directly proportional to their autoxidation rates in vitro, suggesting that reactive species formed during oxidation may be involved in the initiation of this toxic effect."( Structure-activity relationships in the myotoxicity of ring-methylated p-phenylenediamines in rats and correlation with autoxidation rates in vitro.
Fowke, EA; Hoggard, GK; Manns, E; Munday, R, 1990
)
0.28
"Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin."( Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Carrera, CJ; Carson, DA; Kubota, M; Seto, S; Wasson, DB, 1985
)
0.27
"The effects of acetaminophen and its major toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), have been investigated in hepatocytes isolated from 3-methylcholanthrene-pretreated and -untreated rats, respectively."( The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+.
Moldéus, P; Moore, G; Moore, M; Nelson, S; Orrenius, S; Thor, H, 1985
)
0.27
"8 nmol/mg for pirenzepine and 71 nmol/mg for chloroquine, a compound which has been described as provoking toxic side-effects in melanin-containing tissues and adjacent structures."( Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity.
Debing, I; Ijzerman, AP; Vauquelin, G, 1988
)
0.27
" The toxic electrophile produced by cytochrome P-450 oxidation of acetaminophen, N-acetyl-p-benzoquinoneimine, is reduced rapidly by NADH in aqueous solution."( Mechanism by which ethanol diminishes the hepatotoxicity of acetaminophen.
Nelson, SD; Slattery, JT; Thummel, KE, 1988
)
0.27
"A major concern of contemporary medicine is the adverse effects resulting from the use of prescribed and over-the-counter pharmacologic agents."( Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity.
Bidlack, WR; Brown, RC; Mohan, C, 1986
)
0.27
" When this oxidation was minimized by rapid manipulations or inhibited by ascorbic acid, cytotoxicity was reduced or eliminated, suggesting that the nitroso-derivative may be the toxic metabolite."( Cytotoxicity of oxidative metabolites of procainamide.
Jones, JE; Rubin, RL; Uetrecht, JP, 1987
)
0.27
" Of the scavengers of toxic oxygen metabolites tested only the hydroxyl radical scavenger sodium benzoate inhibited cytotoxicity."( Importance of oxidative metabolism in T cell cytotoxicity: a comparison of cloned T cells and spleen cells.
Franks, D; Thorne, KJ, 1983
)
0.27
" However, hydrogen peroxide was toxic to cells at lower concentrations and at shorter exposure times relative to aldehydes."( Aldehyde dehydrogenase and cytotoxicity of purified bovine serum amine oxidase and spermine in Chinese hamster ovary cells.
Agostinelli, E; Averill-Bates, DA; Mondovi, B; Przybytkowski, E,
)
0.13
"The free radicals nitric oxide and superoxide anion react to form peroxynitrite (ONOO-), a highly toxic oxidant species."( DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite.
O'Connor, M; Salzman, AL; Szabó, C; Zingarelli, B, 1996
)
0.29
" The method is rapid, precise, and lacks any toxic byproduct."( In vitro correlation between two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium laurylsulfate cytotoxicity.
Coiffard, C; Coiffard, LJ; De Roeck-Holtzhauer, Y; Rivalland, P; Verhulst, C, 1998
)
0.3
"Aminochrome was found to be toxic in a mouse-derived neuronal cell line (CNh)."( Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?
Armero, JM; Arriagada, C; Caviedes, P; Caviedes, R; Dagnino-Subiabre, A; Segura-Aguilar, J, 2000
)
0.31
" In order to validate the results obtained and to evaluate the capability of the SMP assay to reproduce the toxic effects of the examined compounds on different freshwater species, the EC50 values were compared with literature data from other biological assays regarding both in vitro systems and whole organisms."( Assessment of chloroaniline toxicity by the submitochondrial particle assay.
Agnoli, F; Argese, E; Bettiol, C; Ghirardini, AV; Mazzola, M; Zambon, A, 2001
)
0.31
"The concentration-dependent toxic effects of exogenous noradrenaline (NA, CAS 51-41-2) on acute regional myocardial ischemia (MI) was investigated with and without alpha- and beta-adrenoceptor blockade."( Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts.
Klaus, W; Rump, AF; Schierholz, J, 2002
)
0.31
" These direct toxic effects are mediated by superoxide anion radicals."( Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts.
Klaus, W; Rump, AF; Schierholz, J, 2002
)
0.31
"Previously, it was shown that indole-3-acetic acid (IAA) is a nontoxic prodrug that forms a radical, toxic to tumor cells when activated by peroxidase."( Prooxidant activity and cytotoxic effects of indole-3-acetic acid derivative radicals.
O'brien, PJ; Tafazoli, S, 2004
)
0.32
"A simple and rapid in vitro toxicological assay, utilizing submitochondrial particles (SMP), has been used to evaluate the toxic effects of fifteen herbicides belonging to the phenol and phenoxyalkanoic acid chemical classes."( Study on the toxicity of phenolic and phenoxy herbicides using the submitochondrial particle assay.
Argese, E; Bettiol, C; De Vettori, S; Ghetti, PF; Marchetto, D; Miana, P; Zambon, A, 2005
)
0.33
"Zinc neurotoxicity has been demonstrated in ischemic, seizure, hypoglycemic, and trauma-induced neuronal death where Zn(2+) is thought to be synaptically released and taken up in neighbouring neurons, reaching toxic concentrations."( Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway.
Cai, AL; Sheline, CT; Zipfel, GJ, 2006
)
0.33
" It is concluded that V10 inhibits mitochondrial oxygen consumption and induces membrane depolarization more strongly than V1, pointing out that mitochondria is a toxicological target for V10 and the importance to take into account the contribution of V10 to the vanadate toxic effects."( Mitochondria as a target for decavanadate toxicity in Sparus aurata heart.
Aureliano, M; Gutiérrez-Merino, C; Soares, SS, 2007
)
0.34
" We have explored the mechanisms underlying the collapse of mitochondrial potential (Deltapsi(m)) and loss of [Ca(2+)](c) homeostasis in rat hippocampal neurons in culture following toxic glutamate exposure."( Mechanisms underlying the loss of mitochondrial membrane potential in glutamate excitotoxicity.
Abramov, AY; Duchen, MR,
)
0.13
"We demonstrate that using time-resolved two-photon excitation endogenous fluorescence microscopy, the cadmium (Cd)-induced cellular toxic level can be assessed by the free-to protein-bound reduced nicotinamide adenine dinucleotide (free/bound NADH) ratio in a living cell."( Study of cadmium-induced cytotoxicity using two-photon excitation endogenous fluorescence microscopy.
Li, D; Lin, T; Qu, JY; Yang, MS; Zheng, W,
)
0.13
"Cardiac glycosides, which inhibit the plasma membrane Na(+) pump, are one of the four categories of drug recommended for routine use to treat heart failure, yet their therapeutic window is limited by toxic effects."( Role of mitochondrial dysfunction in cardiac glycoside toxicity.
Brown, DA; Liu, T; O'Rourke, B, 2010
)
0.36
" However, whether Wld(S) can protect non-neuronal cells against toxic chemicals is largely unknown."( Wld(S) reduces paraquat-induced cytotoxicity via SIRT1 in non-neuronal cells by attenuating the depletion of NAD.
Chen, X; Liu, Y; Wang, T; Wu, D; Wu, J; Yu, Q; Zhai, Q; Zhou, X, 2011
)
0.37
" We firstly established the illumination conditions that do not affect mitochondrial structure and calculated the maximum safe light dose to which the cells can be exposed."( Autofluorescence microscopy: a non-destructive tool to monitor mitochondrial toxicity.
Macko, P; Palosaari, T; Rodrigues, RM; Whelan, MP, 2011
)
0.37
" A phenomenological double logistic model was proposed to quantify and relate the observed kinetic changes of fluorescence to the toxic potency of chemical compounds."( Non-invasive monitoring of cytotoxicity based on kinetic changes of cellular autofluorescence.
Bednarkiewicz, A; Rodrigues, RM; Whelan, MP, 2011
)
0.37
" Several ways to increase the method's sensitivity to toxic substances were suggested; conditions were selected to make it possible to determine, with maximum efficiency, the content of toxic substances corresponding to a certain maximum permissible concentration."( Bioluminescent enzymatic rapid assay of water integral toxicity.
Esimbekova, EN; Kondik, AM; Kratasyuk, VA, 2013
)
0.39
"High concentrations of indole are known to be toxic to cells due to perturbations in membrane potential."( Indole toxicity involves the inhibition of adenosine triphosphate production and protein folding in Pseudomonas putida.
Heo, A; Hong, H; Kim, J; Park, W, 2013
)
0.39
"Bupivacaine is one of the most toxic local anesthetics but the mechanisms underlying its neurotoxicity are still unclear."( Nicotinamide adenine dinucleotide (NAD+) repletion attenuates bupivacaine-induced neurotoxicity.
Lai, LY; Li, L; Xu, SY; Zheng, T; Zhou, SQ, 2013
)
0.39
" Furthermore, we show that the induction of cellular NAD(+) levels using dunnione, which targets intracellular NQO1, prevents the toxic effects of cisplatin through the regulation of PARP-1 and SIRT1 activity."( Dunnione ameliorates cisplatin ototoxicity through modulation of NAD(+) metabolism.
Cho, EY; Choe, SK; Khadka, D; Kim, HJ; Kwak, TH; Lee, S; Lee, SB; Oh, GS; Pandit, A; Park, R; Shen, A; Shim, H; So, HS; Yang, SH, 2016
)
0.43
"Topical steroids are known for their anti-inflammatory properties and are commonly prescribed to treat many adverse skin conditions such as eczema and psoriasis."( Longitudinal in vivo tracking of adverse effects following topical steroid treatment.
Arp, Z; Boppart, SA; Bower, AJ; Chaney, EJ; Hughes-Earle, A; Li, J; Marjanovic, M; Zhao, Y, 2016
)
0.43
" In the present study, we investigated whether and how EP chelates Zn(2+) in neurons when it is present at toxic levels."( Neuroprotective effect of ethyl pyruvate against Zn(2+) toxicity via NAD replenishment and direct Zn(2+) chelation.
Kim, HJ; Kim, SW; Lee, HK; Lee, JK; Yoon, SH, 2016
)
0.43
" In addition to its antitumor activity, cisplatin affects normal cells and may induce adverse effects such as ototoxicity, nephrotoxicity, and peripheral neuropathy."( New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity.
Cho, EY; Kim, HJ; Kwak, TH; Kwon, KB; Lee, SB; Oh, GS; Shen, A; Shim, H; So, HS; Yang, SH, 2016
)
0.43
" Yeast suspensions were used to examine the toxic effects of contaminants on the cyclic behaviour of metabolite changes during anaerobic glycolysis."( Effect of the periodic properties of toxic stress on the oscillatory behaviour of glycolysis in yeast-evidence of a toxic effect frequency.
André, C; Gagné, F, 2017
)
0.46
" The data reported here support the hypothesis that QUE rescues the toxic effects of DON or 15ADON due to the similar mechanisms of DON and 15ADON toxicity."( Metabolomic profiling reveals similar cytotoxic effects and protective functions of quercetin during deoxynivalenol- and 15-acetyl deoxynivalenol-induced cell apoptosis.
Jia, BX; Liu, N; Wu, A; Yang, YX; Yu, S, 2020
)
0.56
"Arsenic metabolism enzymes can affect the toxic effects of arsenic."( Gender difference in arsenic biotransformation is an important metabolic basis for arsenic toxicity.
Lai, Y; Muhetaer, M; Wu, J; Xia, R; Yang, M, 2022
)
0.72
" We suggest that these adverse effects are at least in part the result of suppressed activity of sirtuins, particularly Sirtuin1."( Sirtuin deficiency and the adverse effects of fructose and uric acid synthesis.
Garcia-Arroyo, FE; Johnson, RJ; Lanaspa, MA; Nakagawa, T; Rodriguez-Iturbe, B; Sánchez-Lozada, LG, 2022
)
0.72
" Moreover, no severe adverse events were observed during the study period."( Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.
Fukamizu, Y; Kosaka, H; Sakurai, T; Sato, T; Shigekawa, A; Uchida, Y, 2022
)
0.72
" However, the severe adverse effects of cisplatin, particularly kidney toxicity, restrict its clinical and medication applications."( Cisplatin-Induced Kidney Toxicity: Potential Roles of Major NAD
Iskander, A; Yan, LJ, 2022
)
0.72
" Recently, several studies highlighted that Se treatment can effectively antagonize the toxic effects induced by arsenic."( Selenium Supplementation Protects Against Arsenic-Trioxide-Induced Cardiotoxicity Via Reducing Oxidative Stress and Inflammation Through Increasing NAD
Li, WD; Mao, S; Yang, HB; Yuan, W, 2023
)
0.91
" No safety issues, based on monitoring adverse events (AEs), laboratory and clinical measures, were found, and NMN supplementation was well tolerated."( The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
Andhalkar, N; Avhad, G; Kumbhar, V; Lin, Z; Maier, AB; Pendse, S; Tao, R; Thasma, S; Vaidya, A; Yi, L, 2023
)
0.91
" The primary outcome was safety, defined as the frequency of moderate and severe adverse events."( NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C, 2023
)
0.91

Pharmacokinetics

The intracellular nonenzymatic reduction of TAM+ to TAM-H by endogenous NADH was estimated to proceed with an average half-life of 30 min. This potential use of NAD+ or NADH as neuroprotective drugs requires an insight on the pharmacokinetic properties of these compounds.

ExcerptReferenceRelevance
" Based on these values the intracellular nonenzymatic reduction of TAM+ to TAM-H by endogenous NADH was estimated to proceed with an average half-life of 30 min."( An assessment of the role of intracellular reductive capacity in the biological clearance of triarylmethane dyes.
Ozer, I; Tacal, O, 2007
)
0.34
" Pharmacokinetic data suggest an increase in the plasma Css in relation to the escalation of FK866."( The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
Burk, K; Hanauske, AR; Holen, K; Hollywood, E; Saltz, LB, 2008
)
0.35
" The in vivo clearance of tanshinone IIA was acquired from a pharmacokinetic study in rat."( The prediction of the hepatic clearance of tanshinone IIA in rat liver subcellular fractions: accuracy improvement.
Khlentzos, A; Li, J; Li, P; Liu, X; Roberts, MS; Wang, GJ; Zhang, Q, 2008
)
0.35
" This potential use of NAD+ or NADH as neuroprotective drugs requires an insight on the pharmacokinetic properties of these compounds."( Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats.
Fink, H; Rex, A, 2008
)
0.35
" The alkyl side chains of the 2-cycloalkoxyadenosines were fluorinated, and compounds with moderate antibacterial activity and favorable pharmacokinetic properties in rat and dog were identified."( Discovery of bacterial NAD⁺-dependent DNA ligase inhibitors: improvements in clearance of adenosine series.
Albert, R; Chen, B; Gowravaram, M; Hu, H; Huynh, H; Lu, M; Mills, SD; Mullen, GB; Newman, JV; O'Shea, TJ; Rooney, MT; Stokes, SS, 2012
)
0.38

Compound-Compound Interactions

Study addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation. cytogenetic damage induced by ASE plus 3-AB in vitro correlates well with the prevention of NAD depletion in the presence of 3- AB in cells treated with the same alkylating agents.

ExcerptReferenceRelevance
" Thus cytogenetic damage induced by ASE plus 3-AB in vitro and by CBC, ASE, or CP plus 3-AB in vivo correlates well with 1) the prevention of NAD depletion in the presence of 3-AB in cells treated with the same alkylating agents in vitro or in vivo and 2) the in vivo antitumor effect by ASE, CBC, or CP in combination with 3-AB."( Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity, and NAD levels in human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo.
Catsoulacos, P; Dozi-Vassiliades, J; Mioglou, E; Mourelatos, D; Petrou, C, 1990
)
0.28
"05%) combined with dietary choline deficiency was used to study changes in aldehyde dehydrogenase (ALDH) activity during hepatocarcinogenesis in male Sprague-Dawley rats."( Changes in aldehyde dehydrogenase occurring during rat hepatocarcinogenesis induced by ethionine combined with dietary choline deficiency.
Evces, S; Lindahl, R, 1986
)
0.27
"This paper describes a new method, multiphoton excitation fluorescence detection combined with capillary electrophoresis separation."( [Study on multi-photon excited fluorescence combined with capillary electrophoresis].
Ma, WY; Sun, YX; Zhu, F, 2005
)
0.33
" This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan."( Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I, 2006
)
0.33
" In this study we addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation."( NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
Floot, B; van Triest, B; Vens, C; Verheij, M; Zerp, SF, 2014
)
0.4
" Combined with the measurement of each cell's volume, we determined absolute values (μM/h) of the rates of NAD+ synthesis (RS) and breakdown (RB) using a flux assay with a 2H (D)-labeled Nam, together with the absolute NAD+ concentrations in various mammalian cells including primary cultured cardiomyocytes under the physiological conditions and investigated the relations among total cellular Nampt activity, RS, RB, and the NAD+ concentration."( Quantitative analysis of the effects of nicotinamide phosphoribosyltransferase induction on the rates of NAD+ synthesis and breakdown in mammalian cells using stable isotope-labeling combined with mass spectrometry.
Hara, N; Hiyoshi, M; Kobayashi-Miura, M; Osago, H; Tsuchiya, M, 2019
)
0.51
" The FLIM method combined with unsupervised machine learning (FLIM-ML) had a sensitivity and specificity of 90."( Early Detection of Cervical Cancer by Fluorescence Lifetime Imaging Microscopy Combined with Unsupervised Machine Learning.
Fei, Y; Ji, M; Kong, Y; Ma, J; Mi, L; Su, W; Wang, Y; Xue, R; Zhong, J, 2022
)
0.72
" Taken together, the results of the current study suggest that the NAMPT/NAD+ pathway may be a possible therapeutic target for CCA, and FK866 may be a useful medication targeting CCA in combination with cisplatin."( The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth.
Carotenuto, P; Franco, B; Gradilone, SA; Pant, K; Peixoto, E; Richard, S; Roberts, LR; Salati, M; Seelig, DM; Yin, J, 2023
)
0.91

Bioavailability

NAD(+) bioavailability modulates mitochondrial oxidative function and organismal metabolism across the daily cycles of fasting and feeding. Researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR)

ExcerptReferenceRelevance
"- and O2 absorption rate polarographically determined has indicated that about 2% of the absorbed O2 is consumed to form O2-."( [Quantitative determination of the rate of superoxide radical formation in mitochondrial membranes by electron paramagnetic resonance].
Baĭder, LM; Krinitskaia, LA; Rashba, IuE; Vartanian, LS,
)
0.13
" These results indicate that gastric alcohol dehydrogenase activity governs, in part, the systemic bioavailability of ethanol."( Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels.
Baraona, E; Caballeria, J; Lieber, CS; Rodamilans, M, 1989
)
0.28
" The predominant metabolic pathways observed in the present study could be attributed to preponderant bioavailability of NAD+ and NADPH in the intact transfected cells used."( Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family.
Bélanger, A; de Launoit, Y; Durocher, F; Labrie, F; Sanchez, R; Simard, J, 1994
)
0.29
" The reported exclusive bioavailability of the co-factors NADPH and NAD+ in vivo, however, will direct the metabolic pathways in these tissues to sustain the formation of DHT."( 3 Alpha-hydroxysteroid oxidoreductase activities in dihydrotestosterone degradation and back-formation in rat prostate and epididymis.
Benraad, TJ; Smals, AG; Span, PN; Sweep, CG, 1996
)
0.29
" Aim of this open prospective study was to investigate (1) the efficacy of a new developed, parenteral application form of NADH on Parkinsonian symptoms and (2) the influence of bioavailability of levodopa."( Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
Danielczik, S; Gerstner, A; Häcker, R; Kuhn, W; Mattern, C; Müller, T; Przuntek, H; Winkel, R, 1996
)
0.29
"The overall objective of this study was to assess the contribution of an altered bioavailability of nitric oxide (NO) to the leukocyte adhesion and hypoxic stress elicited in the liver by gut ischemia-reperfusion (I/R)."( Role of nitric oxide in gut ischemia-reperfusion-induced hepatic microvascular dysfunction.
Granger, DN; Horie, Y; Wolf, R, 1997
)
0.3
" Dried skim milk with most of its niacin in free form showed 98% niacin equivalent to be bioavailable whereas in pearl millet niacin was in bound form and bioavailability equivalent was only 48 per cent."( Hepatic pyridine nucleotides content in rat--a better indicator for determining available niacin values of food.
Behl, R; Deodhar, AD, 1999
)
0.3
" Altered superoxide production and NO bioavailability have been implicated in contributing to the development of tolerance, an effect that may be ameliorated by the administration of antioxidants."( Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate.
Devine, AB; Dixon, LJ; Hamilton, P; Hanratty, CG; Leahey, WJ; McGrath, LT; McVeigh, GE; Morgan, DG; Wilson, M, 2002
)
0.31
" The rats were injected for 10 days once daily with the doses of NADH used in the bioavailability study (10-100 mg/kg) or vehicle 20 min before the behavioural tests."( Treatment with reduced nicotinamide adenine dinucleotide (NADH) improves water maze performance in old Wistar rats.
Fink, H; Rex, A; Spychalla, M, 2004
)
0.32
" In summary, acute exposure to baicalein impairs eNOS/endothelium-derived nitric oxide-mediated vascular tone in rat aortas through the inhibition of endothelium-derived nitric oxide bioavailability coupled to reduced bioactivity of endothelium-derived nitric oxide and to cyclooxygenase-mediated release of superoxide anions."( Baicalein impairs vascular tone in normal rat aortas: role of superoxide anions.
Achike, FI; Machha, A; Mohd, MA; Mustafa, MR, 2007
)
0.34
" These findings establish bioavailability and potent effects of these nucleosides in stimulating the increase of NAD+ concentrations in mammalian cells."( Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
Chan, NY; Sauve, AA; Yang, T, 2007
)
0.34
" In the gut sac, NADH had a concentration-independent absorption rate of about 5 percent and the in vivo laser-induced fluorescence spectroscopy revealed a relatively quick absorption of NADH starting after a few minute reaching a plateau (about 5 percent ) after 20-30 minutes."( Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats.
Fink, H; Rex, A, 2008
)
0.35
" Uridine and its prodrug triacetyluridine are used to compensate pyrimidine deficiency but their bioavailability is limited."( Converting NADH to NAD+ by nicotinamide nucleotide transhydrogenase as a novel strategy against mitochondrial pathologies during aging.
Olgun, A, 2009
)
0.35
" Finally, we show that yeast nicotinic acid riboside utilization largely depends on uridine hydrolase and nicotinamide riboside kinase and that nicotinic acid riboside bioavailability is increased by ester modification."( Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism.
Belenky, P; Brenner, C; Christensen, KC; Gazzaniga, F; Pletnev, AA, 2009
)
0.35
" GTN bioactivation measured as activation of purified soluble guanylate cyclase or release of NO in the presence of WT- or E268Q-ALDH2 was markedly potentiated by superoxide dismutase, suggesting that bioavailability of GTN-derived NO is limited by co-generation of superoxide."( Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2.
Baral, PK; Beretta, M; Gorren, AC; Gruber, K; Koesling, D; Mayer, B; Russwurm, M; Schmidt, K; Wenzl, MV; Zeller, A, 2009
)
0.35
" Bioavailability and compartmentalization of NAD(+) have become highly relevant issues that we need to understand in order to elucidate how NAD(+) acts both as a readout of the metabolic milieu and as an effector triggering appropriate cellular adaptations."( NAD+ as a signaling molecule modulating metabolism.
Auwerx, J; Cantó, C, 2011
)
0.37
" As SIRT1 deacetylase activity is dependent on NAD(+) levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD(+) bioavailability has received increasing attention."( Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.
Choi, SE; Fu, T; Kang, Y; Kemper, B; Kemper, JK; Kim, DH; Lee, KW; Li, X; Seok, S; Yu, E, 2013
)
0.39
" Among others effects of thio-DMA(V) on eight cell death related endpoints, cell cycle distribution, genotoxicity, cellular bioavailability as well as for the first time its impact on DNA damage induced poly(ADP-ribosyl)ation were investigated and compared to effects induced by arsenite."( Toxicological properties of the thiolated inorganic arsenic and arsenosugar metabolite thio-dimethylarsinic acid in human bladder cells.
Beneke, S; Berndt, S; Bürkle, A; Ebert, F; Leffers, L; Mangerich, A; Schwerdtle, T; Weber, T, 2014
)
0.4
" Thus, circadian control of NAD(+) bioavailability modulates mitochondrial oxidative function and organismal metabolism across the daily cycles of fasting and feeding."( Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice.
Affinati, AH; Bacsik, DJ; Bass, J; Chandel, NS; Denu, JM; Gius, D; Goetzman, E; Ilkayeva, O; Kobayashi, Y; Kuo, HY; Levine, DC; Marcheva, B; Mrksich, M; Newgard, CB; Omura, C; Peek, CB; Ramsey, KM; Sena, LA; Yu, W, 2013
)
0.39
" Additional studies with nicotinamide riboside in models of Alzheimer's disease indicate bioavailability to brain and protective effects, likely by stimulation of brain NAD synthesis."( Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Chi, Y; Sauve, AA, 2013
)
0.39
" Similar effects are obtained by germ line deletion of major NAD-consuming enzymes, suggesting that the bioavailability of NAD is limiting for maximal oxidative capacity."( Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism.
Agarwal, B; Baur, JA; Dávila, A; Davis, JG; Frederick, DW; Michan, S; Nakamaru-Ogiso, E; Puchowicz, MA, 2015
)
0.42
" The coenzyme bioavailability may be significantly affected by these reactions, with ensuing major impact on energy metabolism, cell survival, and aging."( Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues.
Orsomando, G; Raffaelli, N; Ruggieri, S; Sorci, L, 2015
)
0.42
" However, triclosan is less useful as an antitubercular drug due to its low bioavailability and therefore, in order to overcome this difficulty, many derivatives of triclosan were prepared."( Anti-tubercular drug development: computational strategies to identify potential compounds.
Deka, RC; Jha, AN; Rajkhowa, S, 2015
)
0.42
" While the maintenance of NAD(+) homeostatic levels assures an adequate environment for host cell survival and proliferation, fluctuations in NAD(+) or biosynthetic precursors bioavailability have been described during host-pathogen interactions, which will interfere with pathogen persistence or clearance."( Exploring NAD+ metabolism in host-pathogen interactions.
Belinha, A; Estaquier, J; Gaifem, J; Laforge, M; Mesquita, I; Silvestre, R; Varela, P; Vergnes, B, 2016
)
0.43
" Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD."( Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Abu Aboud, O; Baloglu, E; Chen, X; Chmiel, KJ; Dionne, LK; Hwang, VJ; Li, X; Mahjoub, MR; Senapedis, W; Shim, K; Trott, J; Weiss, RH; Zhou, X, 2017
)
0.46
" Additionally, in the SHRtr group, superoxide levels were significantly decreased, nitric oxide bioavailability was improved, and the levels of the nicotinamide adenine dinucleotide oxidase subunit isoform 4 protein were decreased compared to the SHRsd group."( Aerobic Swim Training Restores Aortic Endothelial Function by Decreasing Superoxide Levels in Spontaneously Hypertensive Rats.
Bechara, LRG; de Sousa, LGO; Fernandes, T; Jordão, CP; Oliveira, EM; Ramires, PR; Tanaka, LY, 2017
)
0.46
" A prodrug strategy was also investigated to address the problem of low aqueous solubility and low bioavailability of the antitumor agent CHM-1."( CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells.
Ho, CT; Hung, CH; Hung, CM; Kuo, SC; Lin, YC; Liu, BL; Liu, CW; Way, TD, 2018
)
0.48
" Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms."( Potential Therapeutic Benefit of NAD
André, H; Cimaglia, G; Morgan, JE; Votruba, M; Williams, PA, 2020
)
0.56
" Many metabolites associated with poor outcomes are substrates of NAD(P)-dependent enzymatic processes, while alterations in NAD cofactors rely on bioavailability of dietary B-vitamins thiamine, riboflavin and pyridoxine."( A metabolomic endotype of bioenergetic dysfunction predicts mortality in critically ill patients with acute respiratory failure.
Benton, R; Files, DC; Flores, L; Gandotra, S; Gillespie, MN; Harrod, KS; Kean, EA; Langley, RJ; Lovato, J; Luckett, P; Migaud, ME; Morris, PE; Mostellar, MM; Mowry, M; Purcell, LD; Thompson, JW, 2021
)
0.62
" Here, we explored how NAD+ bioavailability controls adipogenic differentiation from hMSC."( Coordinated metabolic transitions and gene expression by NAD+ during adipogenesis.
Aguilar-Arnal, L; Alarcón Del Carmen, A; Cortés-Morales, VA; del Toro-Ríos, X; Fajardo-Orduña, GR; Montesinos, JJ; Noriega, LG; Orozco-Solís, R; Sánchez-Ramírez, E; Stringari, C; Tovar, AR; Ung, TPL, 2022
)
0.72
" Due to its beneficial effects and to the evidence of the reduction of NAD bioavailability with aging, researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR), believing that it will reduce the RGC vulnerability to external stressors, such as increased IOP."( The use of Nicotinamide and Nicotinamide riboside as an adjunct therapy in the treatment of glaucoma.
Costa, VP; Goulart Nacácio E Silva, S; Occhiutto, ML, 2023
)
0.91
" However, the impact of NAD bioavailability on DSB repair remains poorly characterized."( The Impact of NAD Bioavailability on DNA Double-Strand Break Repair Capacity in Human Dermal Fibroblasts after Ionizing Radiation.
Kropotov, A; Nikiforov, A; Solovjeva, L; Svetlova, M, 2023
)
0.91
" For the pharmacokinetics, NAD-A showed double peaks absorption character when administered with single compound, but with higher relative bioavailability when administered with CP extracts with the similar dosage."( UPLC-QTOF-MS/MS assisted UPLC-TQ-MS/MS strategy to comparatively investigate the rat pharmacokinetics of N-acetyldopamine oligomers derived from Cicadae Periostracum.
Guo, MF; Li, SL; Long, F; Mao, Q; Xu, JD; Zhang, HH; Zhong, P; Zhou, J; Zhou, SS; Zhu, H, 2023
)
0.91
" NAD+ levels decrease throughout life; age-related decline in NAD+ bioavailability has been postulated to be a contributor to many age-related diseases."( Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns.
Baur, JA; Bhasin, S; Migaud, M; Musi, N; Seals, D, 2023
)
0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

NadH/NAD+ ratio is a mechanism underlying hepatic triglyceride deposition after acute ethanol dosing. We found that co-incubation of NAD dose-dependently attenuated neurotoxicity mediated by Aβ25-35 and Aβ1-42 in cultured rat cortical neurons.

ExcerptRelevanceReference
" 48 h after dosage of [3H]rifampicin (33 mg/kg) to rats, 29-2 +/- 4-1 (S."( Implication of rifampicin-quinone in the irreversible binding of rifampicin to macromolecules.
Bolt, HM; Remmer, H, 1976
)
0.26
" The changes in H+ fluxes may account for the glucose-induced decrease in K+ and Ca2+ fractional outflow rate, all three parameters displaying hyperbolic-like dose-response curves with half-maximal values at noninsulinotropic glucose concentrations."( Insulin release: the fuel hypothesis.
Herchuelz, A; Hutton, JC; Malaisse, WJ; Sener, A, 1979
)
0.26
" Dose-response curves for glucagon-mediated changes in cyclic AMP concentration and glucose output indicated that under oxidized conditions the ability of glucagon to alter each parameter was decreased without affecting the concentration of hormone at which half-maximal effects occurred."( Responsiveness to glucagon by isolated rat hepatocytes controlled by the redox state of the cytosolic nicotinamide--adenine dinucleotide couple acting on adenosine 3':5'-cyclic monophosphate phosphodiesterase.
Clark, MG; Jarrett, IG, 1978
)
0.26
" A similar ethanol dose-response inhibition curve was also observed when either whole or homogenized cells were stimulated by dibutyryl cyclic AMP."( Ethanol inhibits testosterone biosynthesis by direct action on Leydig cells.
Ellingboe, J; Varanelli, CC, 1979
)
0.26
" Experiments were divided into three groups: in group A, a 5000 ng dose of OC-5186 was administered via the peripheral vein, 1000 ng via the portal vein, and 200 ng/ml in University of Wisconsin (UW) solution; in group B, the OC-5186 dosage was ten times greater than that in group A; in group C (control group), liver procurement and storage were performed without OC-5186."( Protective effect of a prostaglandin oligomer on liver mitochondria in situ: time-shared measurements of fluorescence and reflectance in the cold-preserved rat liver.
Fujita, T; Hayashi, M; Kitai, T; Ohnishi, ST; Ozawa, K; Tanaka, A; Tokuka, A; Yamaoka, Y, 1992
)
0.28
" NADPH shifts the dose-response curve of NO to the left and possibly increases, in this way, the ADP-ribosylation reaction under physiological conditions."( NADPH: a stimulatory cofactor for nitric oxide-induced ADP-ribosylation reaction.
Brüne, B; Dimmeler, S; Lapetina, EG, 1992
)
0.28
" However, the dose-response curves were markedly shifted to the right in the cells from diabetic rats."( Evidence for impaired coupling of receptors to Gi protein in adipocytes from streptozocin-induced diabetic rats.
Green, A; Johnson, JL, 1991
)
0.28
" It is suggested that continuous application of a high dosage of ascorbic acid might be a useful approach in neuroblastoma therapy."( Ascorbic acid enhances the effects of 6-hydroxydopamine and H2O2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH.
Bruchelt, G; Cochrane, CG; Niethammer, D; Schraufstätter, IU, 1991
)
0.28
" Higher concentrations of NADH relative to phenol were necessary to increase the intensity of staining and to ensure a wide dose-response range of color production with respect to the applied enzyme activities."( A tetrazolium method for staining peroxidase labels in blotting assays.
Hanada, T; Ichikawa, E; Taketa, K, 1986
)
0.27
" Dose-response curves of these components revealed that the photoactivatable aryl azido derivative has retained most of the inhibitory activity displayed by the parent substance."( Photoaffinity labelling of mitochondrial NADH: ubiquinone reductase with pethidine analogues.
Werner, S, 1989
)
0.28
" The dose-response curve for insulin stimulation of glucose transport was strongly shifted to the right by pertussis-toxin treatment [EC50 (half-maximally effective insulin concn."( Role of guanine nucleotide regulatory proteins in insulin stimulation of glucose transport in rat adipocytes. Influence of bacterial toxins.
Ciaraldi, TP; Maisel, A, 1989
)
0.28
" The effect of NADH was dependent on the dosage and the severity of the case."( Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.
Birkmayer, GJ; Birkmayer, W,
)
0.13
" With H2O2 extensive DNA damage and NAD depletion were observed, while at a higher H2O2 dosage ATP also became depleted."( Effects of lethal exposure to hyperoxia and to hydrogen peroxide on NAD(H) and ATP pools in Chinese hamster ovary cells.
Gille, JJ; Joenje, H; Mullaart, E; van Berkel, CG; Vijg, J, 1989
)
0.28
"5- to 3-fold increase in cAMP followed by a return to basal levels, whereas the secretory response saturated and remained stable; (iii) permeant cAMP analogs consistently enhanced secretion at low doses and inhibited at higher doses, but the peak enhancement was always much less than that achieved by an optimal dose of CT; (iv) the selective phosphodiesterase inhibitor Ro 20-1724 exhibited similar biphasic dose-response curves, the maximum enhancement again being small compared to that caused by CT itself."( Cholera toxin potentiates IgE-coupled inositol phospholipid hydrolysis and mediator secretion by RBL-2H3 cells.
McCloskey, MA, 1988
)
0.27
" one hour before ethanol), caused increases of up to 23-fold in the hepatic acetaldehyde level, without influencing the cytosolic NAD+:NADH ratio in ethanol dosed rats, while significantly reducing the ethanol elimination rate by up to 44%, compared with controls."( The roles of the hepatocellular redox state and the hepatic acetaldehyde concentration in determining the ethanol elimination rate in fasted rats.
Chakraborty, J; Ryle, PR; Thomson, AD, 1985
)
0.27
" administration of the mycotoxin to the animals at 3 dosage levels (0."( The metabolism of zearalenone in subcellular fractions from rabbit and hen hepatocytes and its estrogenic activity in rabbits.
Di Lauro, FM; Fadini, L; Montesissa, C; Pompa, G, 1986
)
0.27
" The tests conducted at different stages of cell culturing established a relationship between the proliferative response of cells, on the one hand, and the dosage and time of injection of nucleotide into cell culture, on the other."( [Proliferative response of HeLa and Hep2 cell lines to exogenous nucleotides].
Khachaturova, TS; Mkrtchian, LN, 1985
)
0.27
" The effect of perezone on mitochondrial Ca2+ release follows a dose-response relationship and is dependent of the reduction of the drug."( Ca2+ releasing effect of perezone on adrenal cortex mitochondria.
Cárabez, A; Chávez, E; Cuéllar, A, 1987
)
0.27
"The role of the increased hepatocellular redox-state [( NADH]/[NAD+] ratio) as a mechanism underlying hepatic triglyceride deposition after acute ethanol dosing has been investigated in the rat."( The role of the hepatocellular redox state in the hepatic triglyceride accumulation following acute ethanol administration.
Chakraborty, J; Ryle, PR; Thomson, AD, 1986
)
0.27
" An intermediate dosage decreased cerebral glucose utilization in the inferior olivary nuclei, but increased it in the fastigial, interpositus, red, dentate, vestibular, posterior mamillary, and habenular nuclei."( Oxidative metabolism and acetylcholine synthesis during acetylpyridine treatment.
Blass, JP; Gibson, GE, 1985
)
0.27
" By contrast, the movement of a mitochondrion-associated marker enzyme, diphosphopyridine nucleotide diaphorase, was not perceptibly affected (in the submaximal dosage range), which seems to signify that the proximo-distal shift of mitochondria, for which the slow axonal flow acts as carrier, has gone on uninterruptedly."( Neuronal dynamics and axonal flow. IV. Blockage of intra-axonal enzyme transport by colchicine.
Kreutzberg, GW, 1969
)
0.25
"5 times increased molar dosage required to produce islet NAD depression comparable to that of streptozotocin, 150 mg/kg."( Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide.
Anderson, T; Cooney, DA; McMenamin, MG; Schein, PS, 1974
)
0.25
" The NADP+NADPH(2) was little changed in the early hours after dosing with thioacetamide but had decreased by approx."( Liver nucleotides in acute experimental liver injury induced by dimethylnitrosamine and by thioacetamide.
Sawyer, BC; Slater, TF, 1966
)
0.24
" after dosing but showed a partial recovery at the 4hr."( Nicotinamide-adenine dinucleotides in acute liver injury induced by ethionine, and a comparison with the effects of salicylate.
Sawyer, BC; Slater, TF, 1966
)
0.24
"Comparisons were made of the dose-response and time-course characteristics of nicotinamide (NIC) and its metabolite, N1-methylnicotinamide (MNIC), protection from alloxan-induced diabetes in mice."( Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice.
Falany, J; Fischer, LJ; Fisher, R, 1983
)
0.27
" There is a dramatic inverse dose-response relationship between triiodothyronine levels and NAD-G3PDH activity."( Triiodothyronine depresses the NAD-linked glycerol-3-phosphate dehydrogenase activity of cultured neonatal rat heart cells.
Freerksen, DL; Hartzell, CR; Schroedl, NA, 1984
)
0.27
" In a dose-response study, injection of varying amounts of the drug decreased NAD pools in the hepatoma in a dose-dependent fashion."( Tiazofurin-induced selective depression of NAD content in hepatoma 3924A.
Faderan, MA; Liepnieks, JJ; Lui, MS; Weber, G, 1984
)
0.27
" All 3 tester strains showed a dose-response relationship with dimethylnitrosamine (10-125 mumoles per plate) after NADH-supported activation."( Mutagenesis in Salmonella after NADH-dependent microsomal activation of dimethylnitrosamine.
Fong, LY; Lee, KM; Lin, HJ, 1982
)
0.26
" An exponential dose-response relation was obtained between NADPH and T3 generated."( On the role of NADPH and glutathione in the catalytic mechanism of hepatic thyroxine 5'-deiodination.
Maruyama, S; Nomura, K; Sato, T, 1981
)
0.26
" In order to estimate the contractile potency of acetylcholine (ACh), dose-response curves of ACh and nor-epinephrine (NE) were compared."( Significance of glucose for mechanical activity, flavin and pyridine nucleotide oxidation-reduction changes in isolated rat portal veins under ACh-stimulation.
Betz, E; Heinle, H; Linke, AM,
)
0.13
" Although there was no appreciable inhibition of the reduction of pyridine nucleotide at dosage levels less than 150 mg PMG/kg, the extent of inhibition increased as the dose was raised to 240 mg PMG/kg."( Inhibition of succinate-linking reduction of pyridine nucleotide in rat liver mitochondria 'in vivo' by N-(phosphonomethyl)glycine.
Bababunmi, EA; Olorunsogo, OO, 1980
)
0.26
"To inhibit nitric oxide synthase, several dosing regimens of NG-nitro-L-arginine methyl ester (L-NAME) were used (5 or 50 mg/kg IP, twice a day for 4 days, or 30 mg/kg IV) in gerbils."( Nitric oxide inhibition aggravates ischemic damage of hippocampal but not of NADPH neurons in gerbils.
Bernardi, G; Iannone, M; Morello, M; Nisticò, G; Sancesario, G, 1994
)
0.29
" Ergothioneine, independently from the dosage used, failed to: (i) increase recovery of developed pressure upon reperfusion (14."( In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart.
Bernocchi, P; Cargnoni, A; Ceconi, C; Curello, S; Ferrari, R, 1995
)
0.29
" The concentration of compounds causing 50% inhibition of enzyme activity was determined from dose-response curves."( The Entner-Doudoroff pathway in Helicobacter pylori.
Burns, BP; Hazell, SL; Mendz, GL, 1994
)
0.29
" We conclude that the very low dose response cannot be extrapolated from usual dose-response analyses."( Response of human keratinocytes to extremely low concentrations of N-methyl-N'-nitro-N-nitrosoguanidine.
Althaus, FR; Kleczkowska, HE, 1996
)
0.29
" Ischemic phase damage was addressed by comparing the dose-response effects of controls vs."( Effect of high-energy phosphates and free radical scavengers on replant survival in an ischemic extremity model.
Ablove, RH; Moy, OJ; Peimer, CA; Severin, CM; Sherwin, FM, 1996
)
0.29
" It is concluded that trimetazidine at an optimal dosage of 10 mg/kg/day protects mitochondria against the deleterious effects of ischemia-reperfusion."( Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function.
Cherrah, Y; Elimadi, A; Lamchouri, F; Morin, D; Sapena, R; Settaf, A; Tillement, JP, 1998
)
0.3
" This dosage can be used to study the barrier properties of the corneocyte layer without destroying the artificial skin."( In vitro correlation between two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium laurylsulfate cytotoxicity.
Coiffard, C; Coiffard, LJ; De Roeck-Holtzhauer, Y; Rivalland, P; Verhulst, C, 1998
)
0.3
"PBLs from 18 healthy donors were incubated in vitro with different concentrations of NADH to generate dose-response curves."( Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes.
Birkmayer, J; Gebauer, F; Kunze, R; Nadlinger, K, 2001
)
0.31
" Here we show that increased dosage of NPT1, encoding a nicotinate phosphoribosyltransferase critical for the NAD(+) salvage pathway, increases Sir2-dependent silencing, stabilizes the rDNA locus, and extends yeast replicative life span by up to 60%."( Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels.
Anderson, RM; Bitterman, KJ; Cohen, H; Gordon, JI; Lin, SS; Manchester, JK; Medvedik, O; Sinclair, DA; Wood, JG, 2002
)
0.31
" Human endothelial cells were exposed to LPS 50 microg/ml and IFN-gamma 50 ng/ml for 72 hours, and liposomal ATP and NAD+ treatments were dosed at 0 and 24 hours."( Liposomal atp or NAD+ protects human endothelial cells from energy failure in a cell culture model of sepsis.
Carcillo, JA; Dubey, RK; Gillepsie, DG; Han, YY; Huang, L; Jackson, EK,
)
0.13
" Restoration of cerebral energy metabolism by adequate dosage of HBO2 may become an important factor for recovery of brain activities after CO poisoning."( Hyperbaric oxygenation affects rat brain function after carbon monoxide exposure.
Mayevsky, A; Meilin, S; Rogatsky, GG; Thom, SR; Zarchin, N, 2002
)
0.31
" 6-Hydroxydopamine (6-OHDA) treatment markedly reduced, in a dose-response fashion, chromaffin cell viability."( Chromaffin cell death induced by 6-hydroxydopamine is independent of mitochondrial swelling and caspase activation.
Ceña, V; Galindo, MF; González-García, C; Jordán, J, 2003
)
0.32
" This is 175 times the recommended daily dosage of 1 ENADA tablet per day."( Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats.
Birkmayer, JG; Nadlinger, K, 2002
)
0.31
" Increased dosage of Nampt, but not Nmnat, increased the total cellular NAD level and enhanced the transcriptional regulatory activity of the catalytic domain of Sir2alpha recruited onto a reporter gene in mouse fibroblasts."( The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.
Grimm, AA; Imai, S; Revollo, JR, 2004
)
0.32
" A dose-response was examined with each of these solvents."( The effects of organic solvents on poly(ADP-ribose) polymerase-1 activity: implications for neurotoxicity.
Banasik, M; Persad, AS; Stedeford, T; Strosznajder, RP; Tanaka, S; Ueda, K, 2004
)
0.32
"The present study was designed to provide further information about the relevance of raised urinary levels of N-methylnicotinamide (NMN), and/or its metabolites N-methyl-4-pyridone-3-carboxamide (4PY) and N-methyl-2-pyridone-3-carboxamide (2PY), to peroxisome proliferation by dosing rats with known peroxisome proliferator-activated receptor alpha (PPARalpha) ligands [fenofibrate, diethylhexylphthalate (DEHP) and long-chain fatty acids (LCFA)] and other compounds believed to modulate lipid metabolism via PPARalpha-independent mechanisms (simvastatin, hydrazine and chlorpromazine)."( Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation.
Connor, SC; Delaney, J; Haselden, JN; Hodson, MP; Holder, JC; Hutton, KA; Kenny, SP; McGill, PJ; Sweatman, BC; Thakkar, H; Waterfield, CJ, 2005
)
0.33
" We previously reported that an increased dosage of Sirt1 in pancreatic beta cells enhances glucose-stimulated insulin secretion (GSIS) and improves glucose tolerance in beta cell-specific Sirt1-overexpressing (BESTO) transgenic mice at 3 and 8 months of age."( Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice.
Imai, S; Mills, KF; Ramsey, KM; Satoh, A, 2008
)
0.35
" Rather, NAD potentiated ATP-dependent P2X(7)R activation as indicated by a left shift in the ATP dose-response relationship."( Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells.
Brass, A; Dubyak, GR; Haag, F; Hong, S; Koch-Nolte, F; Schilling, WP; Schwarz, N; Seman, M, 2009
)
0.35
" However, group VI did not show the best results for oxidative metabolism, probably indicating that the dosage they were given was high for this protocol."( Effects of low-level laser therapy on the oxidative metabolism and matrix proteins in the rat masseter muscle.
Dias, FJ; Fonseca, MJ; Issa, JP; Iyomasa, MM; Leão, JC; Regalo, SC; Siéssere, S; Vicentini, FT, 2011
)
0.37
" The slo2 growth retardation phenotypes are largely suppressed by supplying sugars or increasing light dosage or the concentration of CO₂."( SLO2, a mitochondrial pentatricopeptide repeat protein affecting several RNA editing sites, is required for energy metabolism.
Brennicke, A; Craddock, C; Denecke, J; Dugardeyn, J; Eastmond, P; Gerats, T; Karampelias, M; Kühn, K; Meyer, EH; Peters, J; Smalle, J; Takenaka, M; Van Der Straeten, D; Zhang, C; Zhu, Q, 2012
)
0.38
" A high dose of resveratrol activated AMPK in a SIRT1-independent manner, demonstrating that resveratrol dosage is a critical factor."( SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.
Agarwal, B; Baur, JA; Coppari, R; Davis, JG; de Cabo, R; Duarte, FV; Gomes, AP; Hafner, A; Hubbard, BP; Ling, AJ; Martin-Montalvo, A; Moaddel, R; North, BJ; Palmeira, CM; Price, NL; Ramadori, G; Rolo, AP; Sinclair, DA; Teodoro, JS; Varamini, B; Varela, AT; Ye, L, 2012
)
0.38
"A mouse model of ovarian cancer was created by dosing with 4-vinylcyclohexene diepoxide, which induces follicular apoptosis (simulating menopause), and 7,12-dimethylbenz[a]anthracene, a known carcinogen."( Two-photon excited fluorescence imaging of endogenous contrast in a mouse model of ovarian cancer.
Barton, JK; Brewer, MA; Hoyer, PB; Marion, SL; Rice, PF; Utzinger, U; Watson, JM, 2013
)
0.39
" The ME-R model is able to simulate: i), the shape and order of magnitude of H(2)O(2) emission and dose-response kinetics observed after treatment with inhibitors of the GSH or Trx scavenging systems and ii), steady and transient behavior of ΔΨ(m) and NADH after single or repetitive pulses of substrate- or uncoupler-elicited energetic-redox transitions."( Integrating mitochondrial energetics, redox and ROS metabolic networks: a two-compartment model.
Aon, MA; Cortassa, S; Kembro, JM; O'Rourke, B; Winslow, RL, 2013
)
0.39
" At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxisomal bifunctional enzyme (ECHD) and acyl-CoA oxidase 1 (ACOX1), and induces excessive accumulation of long chain fatty acids (LCFA) and very long chain fatty acids (VLCFA)."( Uridine prevents fenofibrate-induced fatty liver.
Le, TT; Pizzorno, G; Urasaki, Y, 2014
)
0.4
" Dose-response curves for FAO were constructed and the highest non-effective dose (typically 1-10 nM) was used with either leucine (0."( Synergistic effects of polyphenols and methylxanthines with Leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes.
Bruckbauer, A; Zemel, MB, 2014
)
0.4
" We found that co-incubation of NAD dose-dependently attenuated neurotoxicity mediated by Aβ25-35 and Aβ1-42 in cultured rat cortical neurons, with the optimal protective dosage at 50 mM."( NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons.
Hwang, CS; Tang, CM; Wu, MF; Yang, DI; Yin, JH, 2014
)
0.4
" In this study we intended to confirm the protective effect of nicotinamide adenine dinucleotide (NAD), investigate the optimal administration dosage and time of NAD, and identify the relationship between silence signal regulating factor 1 (SIRT1) and axonal degeneration."( Roles of NAD in Protection of Axon against Degeneration via SIRT1 Pathways.
Ding, ZX; Guo, WH; Hao, J; Hu, YL; Li, GB; Li, HY; Qi, XX; Sun, JH; Wu, Q; Zhang, J, 2016
)
0.43
" Notably, Sirtuin 1 (Sirt1) gene expression was also significantly up-regulated in a dose-response pattern."( Dietary proanthocyanidins boost hepatic NAD(+) metabolism and SIRT1 expression and activity in a dose-dependent manner in healthy rats.
Aragonès, G; Ardid-Ruiz, A; Arola, L; Bladé, C; Correig, X; Rodríguez, MA; Suárez, M; Vinaixa, M, 2016
)
0.43
" These data suggest that administration of NMN at a proper dosage has a strong protective effect against ischemic brain injury."( Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia.
Kristian, T; Long, A; Owens, K; Park, JH, 2016
)
0.43
" In mice, optimization of OT-82 dosing and dietary niacin further expanded the compound's therapeutic index."( OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Andrianova, EL; Antoch, MP; Chernov, MV; Chernova, OB; Gudkov, AV; Gupta, M; Haber, M; Henderson, MJ; Joshi, S; Kazyulkin, D; Komarov, PG; Kononov, E; Korotchkina, L; Krasnov, P; Lock, RB; Middlemiss, S; Norris, MD; Polinsky, A; Somers, K; Tian, Y; Toshkov, I; Veith, J; Vujcic, S, 2020
)
0.56
" NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg."( Nicotinamide riboside with pterostilbene (NRPT) increases NAD
Dellinger, R; Guarente, LP; Parikh, SM; Rhee, EP; Simic, P; Vela Parada, XF, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" The participants were randomized into four groups: the low dosage group (300 mg/day NMN), the medium dosage group (600 mg/day NMN), the high dosage group (1200 mg/day NMN), and the control group (placebo)."( Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
Hao, X; Hu, M; Liao, B; Wang, D; Zhang, X; Zhao, Y, 2021
)
0.62
" Here, we investigated whether dosage time affected prednisone effects on muscle bioenergetics."( Muscle mitochondrial remodeling by intermittent glucocorticoid drugs requires an intact circadian clock and muscle PGC1α.
Bass, J; Levine, DC; McNally, EM; Miz, K; Peek, CB; Quattrocelli, M; Wintzinger, M, 2022
)
0.72
" We conducted a systematic review and dose-response meta-analysis, aiming to explore the association between noise exposure and the risk of dementia."( Chronic Noise Exposure and Risk of Dementia: A Systematic Review and Dose-Response Meta-Analysis.
Huang, L; Jiang, F; Lan, Y; Meng, L; Sha, L; Zhang, S; Zhang, Y, 2022
)
0.72
" A dose-response meta-analysis and subgroup analysis were then conducted to detect the association between noise exposure and the risk of dementia by using Stata 14."( Chronic Noise Exposure and Risk of Dementia: A Systematic Review and Dose-Response Meta-Analysis.
Huang, L; Jiang, F; Lan, Y; Meng, L; Sha, L; Zhang, S; Zhang, Y, 2022
)
0.72
" Subsequently, when FA dosage was over 120 mg/L, Anaerolineae were inhibited and heterotrophic bacteria reduced, resulting in the abundance of AOB recovered."( Metagenomic insights into responses of microbial population and key functional genes to fulvic acid during partial nitritation.
Dou, Q; Hao, S; Lan, S; Peng, Y; Wang, X; Wang, Y; Yang, J; Zhang, L; Zhang, R, 2023
)
0.91
" This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN."( The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
Andhalkar, N; Avhad, G; Kumbhar, V; Lin, Z; Maier, AB; Pendse, S; Tao, R; Thasma, S; Vaidya, A; Yi, L, 2023
)
0.91
" Dosing regimens and study durations vary greatly across interventions, and small sample sizes limit data interpretation of physiological outcomes."( Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.
Craighead, DH; Freeberg, KA; Martens, CR; Seals, DR; Udovich, CC, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (5 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements5

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
1Life Science NAD+ Longevity Blood Sugar Support -- 60 Veggie Caps1Life ScienceVitamins & SupplementsUrolithin A, Berberine HCl, Chromium, NAD +, NMN, Alpha-Lipoic Acid, Vanadium2024-11-29 10:47:42
1Life Science NAD+ Longevity Cardiovascular Support -- 60 Veggie Caps1Life ScienceVitamins & SupplementsApigenin, Fisetin, Vitamin B9, NAD +, Vitamin B3, NMN, Vitamin B6, Quercetin, Vitamin B62024-11-29 10:47:42
1Life Science NAD+ Longevity Cognition & Vision Support -- 60 Veggie Caps1Life ScienceVitamins & SupplementsApigenin, Lutein, NAD +, NMN, Zeaxanthin2024-11-29 10:47:42
Aurora NutraScience Mega-Liposomal NAD+ Resveratrol Organic Fruit -- 16 fl ozAurora NutraScienceVitamins & SupplementsNAD+, Resveratrol2024-11-29 10:47:42
Vena Spa Water Radiance Renewal Drink Powder Strawberry Kiwi -- 20 Stick PacketsVenaVitamins & Supplements Citric acid, Vitamin C, Citric acid, Gamma-Aminobutyric Acid, L-Glycine, L-Lysine, Nicotinamide Adenine Dinucleotide2024-11-29 10:47:42

Roles (5)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
hydrogen acceptorA molecular entity that can undergo reduction by the gain of hydrogen atom(s).
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
NADAbbreviation for nicotinamide-adenine dinucleotide when its oxidation state is unknown or unspecified. It is used in metabolic pathways like glycolysis and citric acid cycle.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1,311)

PathwayProteinsCompounds
Glycolysis6132
Transport of small molecules39295
O2/CO2 exchange in erythrocytes811
Erythrocytes take up carbon dioxide and release oxygen811
Organelle biogenesis and maintenance23216
Mitochondrial biogenesis668
Transcriptional activation of mitochondrial biogenesis357
Metabolism14961108
Carbohydrate metabolism173120
Glucose metabolism7642
Gluconeogenesis3031
Fructose metabolism721
Fructose biosynthesis29
Fructose catabolism515
Galactose catabolism410
Formation of xylulose-5-phosphate515
Inositol phosphate metabolism3235
Synthesis of IP2, IP, and Ins in the cytosol517
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism1041
alpha-linolenic acid (ALA) metabolism1031
Linoleic acid (LA) metabolism524
Mitochondrial Fatty Acid Beta-Oxidation2260
mitochondrial fatty acid beta-oxidation of saturated fatty acids942
Beta oxidation of palmitoyl-CoA to myristoyl-CoA313
Beta oxidation of myristoyl-CoA to lauroyl-CoA313
Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA513
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA615
Beta oxidation of octanoyl-CoA to hexanoyl-CoA513
Beta oxidation of hexanoyl-CoA to butanoyl-CoA513
Beta oxidation of butanoyl-CoA to acetyl-CoA314
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids615
Peroxisomal lipid metabolism2552
Alpha-oxidation of phytanate625
Beta-oxidation of pristanoyl-CoA922
Beta-oxidation of very long chain fatty acids821
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Synthesis of PA2215
Sphingolipid metabolism5550
Glycosphingolipid metabolism3031
Metabolism of steroids111135
Cholesterol biosynthesis2249
Bile acid and bile salt metabolism3171
Synthesis of bile acids and bile salts2068
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol1644
Synthesis of bile acids and bile salts via 24-hydroxycholesterol831
Synthesis of bile acids and bile salts via 27-hydroxycholesterol718
Metabolism of steroid hormones2537
Glucocorticoid biosynthesis616
Mineralocorticoid biosynthesis616
Androgen biosynthesis916
Ketone body metabolism1019
Synthesis of Ketone Bodies817
Ketone body catabolism410
Biosynthesis of specialized proresolving mediators (SPMs)13107
Synthesis of Lipoxins (LX)616
Biosynthesis of EPA-derived SPMs625
Biosynthesis of E-series 18(S)-resolvins518
Biosynthesis of DHA-derived SPMs1156
Biosynthesis of D-series resolvins415
Integration of energy metabolism4927
Regulation of insulin secretion3019
The citric acid (TCA) cycle and respiratory electron transport14756
Pyruvate metabolism and Citric Acid (TCA) cycle4146
Pyruvate metabolism2026
Citric acid cycle (TCA cycle)1827
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.11019
Respiratory electron transport9113
Nucleotide metabolism89125
Nucleotide biosynthesis1246
Purine ribonucleoside monophosphate biosynthesis936
Nucleotide catabolism3671
Purine catabolism2051
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Vitamin C (ascorbate) metabolism418
Cobalamin (Cbl, vitamin B12) transport and metabolism1825
Nicotinate metabolism2243
Nicotinamide salvaging1030
Metabolism of folate and pterines1629
Metabolism of fat-soluble vitamins2623
Retinoid metabolism and transport2217
Amino acid and derivative metabolism250260
Serine biosynthesis416
Branched-chain amino acid catabolism2031
Carnitine synthesis416
Histidine catabolism822
Lysine catabolism1031
Proline catabolism311
Tryptophan catabolism1426
Glyoxylate metabolism and glycine degradation2037
Glycine degradation49
Sulfur amino acid metabolism2763
Threonine catabolism514
Choline catabolism614
Biological oxidations150276
Phase I - Functionalization of compounds69175
Ethanol oxidation1216
Phase II - Conjugation of compounds73122
Glucuronidation718
Formation of the active cofactor, UDP-glucuronate310
Methylation1338
Abacavir ADME624
Abacavir metabolism423
DNA Repair25547
Base Excision Repair3523
Resolution of Abasic Sites (AP sites)257
Resolution of AP sites via the multiple-nucleotide patch replacement pathway156
POLB-Dependent Long Patch Base Excision Repair66
DNA Double-Strand Break Repair10313
Homology Directed Repair839
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)799
Processing of DNA double-strand break ends518
HDR through MMEJ (alt-NHEJ)104
Nucleotide Excision Repair847
Global Genome Nucleotide Excision Repair (GG-NER)587
DNA Damage Recognition in GG-NER242
Signaling Pathways1269117
Signaling by Receptor Tyrosine Kinases29335
Signaling by VEGF6225
VEGFA-VEGFR2 Pathway5225
VEGFR2 mediated cell proliferation98
Signaling by TGFB family members847
Signaling by TGF-beta Receptor Complex677
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer326
Downregulation of SMAD2/3:SMAD4 transcriptional activity176
Signaling by GPCR24955
GPCR downstream signalling17252
G alpha (i) signalling events8741
Opioid Signalling2319
G-protein mediated events1615
PLC beta mediated events1514
Visual phototransduction6241
The canonical retinoid cycle in rods (twilight vision)1415
Signaling by NOTCH11314
Pre-NOTCH Expression and Processing2413
Pre-NOTCH Transcription and Translation174
Signaling by WNT14820
TCF dependent signaling in response to WNT1049
Degradation of AXIN472
Signaling by Nuclear Receptors15246
Signaling by Retinoic Acid2431
RA biosynthesis pathway1119
Intracellular signaling by second messengers12614
PI3K/AKT Signaling1138
PTEN Regulation776
Regulation of PTEN stability and activity525
DAG and IP3 signaling1410
Cellular responses to stimuli48356
Cellular responses to stress46954
Cellular response to heat stress709
Regulation of HSF1-mediated heat shock response577
Muscle contraction7721
Cardiac conduction5212
Ion homeostasis1810
Neuronal System16650
Transmission across Chemical Synapses12250
Neurotransmitter release cycle3133
GABA synthesis, release, reuptake and degradation1614
Degradation of GABA210
Neurotransmitter clearance725
Clearance of seratonin313
Metabolism of serotonin211
Cell Cycle53831
Cell Cycle, Mitotic41031
M Phase27921
Mitotic Metaphase and Anaphase15812
FOXO-mediated transcription607
Regulation of FOXO transcriptional activity by acetylation85
Mitotic Anaphase15712
Nuclear Envelope (NE) Reassembly5110
Initiation of Nuclear Envelope (NE) Reformation147
hypusine biosynthesis09
Metabolism of proteins1058144
Post-translational protein modification666112
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation4626
Hypusinylation28
The activation of arylsulfatases24
Disease1278231
Diseases associated with visual transduction710
Retinoid cycle disease events710
Diseases of metabolism69121
Metabolic disorders of biological oxidation enzymes647
Defective AHCY causes HMAHCHD03
Diseases of glycosylation2243
Diseases associated with glycosylation precursor biosynthesis621
Defective GALE causes EDG12
Infectious disease89579
Latent infection - Other responses of Mtb to phagocytosis3233
Tolerance by Mtb to nitric oxide produced by macrophages1121
Cell redox homeostasis88
Uptake and actions of bacterial toxins389
Uptake and function of diphtheria toxin73
Gene expression (Transcription)90249
RNA Polymerase II Transcription72842
Generic Transcription Pathway60839
4-hydroxybenzoate biosynthesis I (eukaryotes)018
phosphatidate biosynthesis (yeast)012
UDP-sugars interconversion017
L-proline biosynthesis I013
L-proline degradation I09
L-proline biosynthesis I (from L-glutamate)013
fatty acid u03B1-oxidation I (plants)08
NAD(P)/NADPH interconversion011
fatty acid u03B2-oxidation II (plant peroxisome)016
brassinolide biosynthesis II025
brassinolide biosynthesis I026
thiazole component of thiamine diphosphate biosynthesis III09
L-proline biosynthesis III (from L-ornithine)010
L-ascorbate biosynthesis I (plants, L-galactose pathway)012
glycolysis IV019
gluconeogenesis III024
formate oxidation to CO214
pyocyanin biosynthesis011
superpathway of proto- and siroheme biosynthesis1638
methylglyoxal degradation III118
L-aspartate degradation II58
nitrobenzene degradation II06
NAD/NADP-NADH/NADPH mitochondrial interconversion (yeast)010
ethylene biosynthesis II (microbes)015
TCA cycle III (animals)023
2-hydroxybiphenyl degradation011
Epigenetic regulation of gene expression11717
Negative epigenetic regulation of rRNA expression456
SIRT1 negatively regulates rRNA expression95
NAD salvage pathway II (PNC IV cycle)012
NAD phosphorylation and transhydrogenation07
Immune System91482
Adaptive Immune System26424
B Cell Activation909
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers245
guanosine nucleotides degradation III012
4-deoxy-L-threo-hex-4-enopyranuronate degradation012
adenosine nucleotides degradation II013
Innate Immune System41475
urate conversion to allantoin II010
nostoxanthin biosynthesis08
hydrogen production II04
ascorbate recycling (cytosolic)010
hydrogen oxidation II (aerobic, NAD)04
UMP biosynthesis III020
xylitol degradation08
L-carnitine biosynthesis014
Fcgamma receptor (FCGR) dependent phagocytosis3211
Role of phospholipids in phagocytosis49
Fc epsilon receptor (FCERI) signaling9013
FCERI mediated Ca+2 mobilization49
C-type lectin receptors (CLRs)8817
L-tyrosine biosynthesis I09
CLEC7A (Dectin-1) signaling7712
CLEC7A (Dectin-1) induces NFAT activation37
wax esters biosynthesis II19
salicylate glucosides biosynthesis II19
2-oxoglutarate decarboxylation to succinyl-CoA07
superpathway of branched chain amino acid biosynthesis030
glycolysis IV (plant cytosol)1347
C4 photosynthetic carbon assimilation cycle, NAD-ME type321
pyruvate decarboxylation to acetyl CoA17
TCA cycle II (plants and fungi)1419
putrescine degradation IV313
inosine 5'-phosphate degradation013
ethanol degradation I07
indigo biosynthesis08
salidroside biosynthesis215
L-tyrosine biosynthesis III09
L-histidine biosynthesis427
dimethylsulfoniopropanoate biosynthesis I (Wollastonia)115
D-galactose degradation I (Leloir pathway)311
(-)-camphor biosynthesis09
L-leucine biosynthesis417
superpathway of thiamine diphosphate biosynthesis III (eukaryotes)324
ephedrine biosynthesis019
aliphatic glucosinolate biosynthesis, side chain elongation cycle118
juniperonate biosynthesis014
methyl ketone biosynthesis (engineered)018
GDP-L-galactose biosynthesis25
superpathway of lipoxygenase628
salicin biosynthesis012
L-glutamate degradation IV516
u03B2-alanine biosynthesis II017
ethanol degradation II413
salicortin biosynthesis017
sulfoquinovosyl diacylglycerol biosynthesis07
ammonia assimilation cycle I213
L-serine biosynthesis I311
superpathway of coenzyme A biosynthesis II (plants)632
glycerol-3-phosphate shuttle16
L-lysine degradation I019
(4S)-carvone biosynthesis116
juvenile hormone III biosynthesis I017
NAD biosynthesis from 2-amino-3-carboxymuconate semialdehyde014
mannitol degradation II113
L-homomethionine biosynthesis215
zerumbone biosynthesis110
folate transformations II721
4-aminobutanoate degradation I19
L-ascorbate degradation IV112
malate-oxaloacetate shuttle II37
arachidonate biosynthesis I (6-desaturase, lower eukaryotes)016
matairesinol biosynthesis019
guanosine nucleotides degradation II125
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle2856
pinitol biosynthesis II016
guanosine ribonucleotides de novo biosynthesis215
alkane biosynthesis II116
L-phenylalanine degradation III112
L-ascorbate biosynthesis II (L-gulose pathway)211
glycolysis I (from glucose 6-phosphate)1220
superpathway of acetyl-CoA biosynthesis112
choline degradation I27
L-leucine degradation I720
ethanol degradation IV013
L-isoleucine degradation I316
L-valine degradation I520
UDP-u03B1-D-galactose biosynthesis23
L-alanine degradation II (to D-lactate)010
adenosine nucleotides degradation I327
lysine degradation II421
D-galactose detoxification617
acetaldehyde biosynthesis I45
brassinosteroid biosynthesis III19
abscisic acid biosynthesis512
pyruvate fermentation to ethanol I19
brassinosteroid biosynthesis II520
lysine degradation III222
NAD biosynthesis III (from nicotinamide)07
pyruvate fermentation to ethanol II28
TCA cycle variation V (plant)1422
dimethylsulfoniopropanoate biosynthesis II (Spartina)021
L-arginine degradation I (arginase pathway)210
brassinosteroid biosynthesis I726
L-proline degradation09
superpathway of purines degradation in plants745
nucleobase ascorbate transport I16
photorespiration823
4-hydroxybenzoate biosynthesis III (plants)115
ureide biosynthesis220
2-oxoisovalerate decarboxylation to isobutanoyl-CoA17
benzoate biosynthesis II (CoA-independent, non-u03B2-oxidative)011
6-gingerol analog biosynthesis (engineered)220
indican biosynthesis010
(+)-camphor biosynthesis111
pyruvate fermentation to (S)-lactate013
4-aminobutanoate degradation IV210
malate-oxaloacetate shuttle I55
NAD de novo biosynthesis I (from aspartate)522
traumatin and (Z)-3-hexen-1-yl acetate biosynthesis819
NAD de novo biosynthesis II (from tryptophan)024
glycine cleavage07
fatty acid u03B1-oxidation I29
sucrose biosynthesis I (from photosynthesis)1124
abietic acid biosynthesis513
superpathway of diterpene resin acids biosynthesis523
4-hydroxybenzoate biosynthesis IV (plants)09
siroheme biosynthesis111
justicidin B biosynthesis116
L-ascorbate biosynthesis I (L-galactose pathway)918
superpathway of C28 brassinosteroid biosynthesis730
glyoxylate cycle813
glycolysis II (from fructose 6-phosphate)1320
iron reduction and absorption125
bixin biosynthesis313
UDP-galactose biosynthesis (salvage pathway from galactose using UDP-glucose)018
noscapine biosynthesis725
pyridine nucleotide cycling (plants)322
UDP-u03B1-D-glucuronate biosynthesis (from UDP-glucose)16
gluconeogenesis I024
superpathway of guanosine nucleotides degradation (plants)227
L-phenylalanine degradation V38
NAD/NADH phosphorylation and dephosphorylation2914
menthol biosynthesis821
superpathway of glyoxylate cycle and fatty acid degradation2529
aerobic respiration III (alternative oxidase pathway)379
guanosine nucleotides degradation I226
L-glutamate degradation I27
aerobic respiration I (cytochrome c)459
phenylethanol biosynthesis914
D-sorbitol degradation I112
purine nucleotides degradation I (plants)334
superpathway of anaerobic sucrose degradation3360
UDP-u03B1-D-xylose biosynthesis59
jasmonic acid biosynthesis621
benzoate biosynthesis III (CoA-dependent, non-u03B2-oxidative)016
fatty acid u03B2-oxidation II (peroxisome)717
thiazole biosynthesis III (eukaryotes)09
L-glutamate biosynthesis IV06
L-ascorbate biosynthesis II (plants, L-gulose pathway)011
tropane alkaloids biosynthesis028
superpathway of hyoscyamine (atropine) and scopolamine biosynthesis039
Glutamate and glutamine metabolism1127
Phenylalanine and tyrosine metabolism1132
Phenylalanine metabolism621
Infection with Mycobacterium tuberculosis7442
Escape of Mtb from the phagocyte15
Phagocyte cell death caused by cytosolic Mtb15
nitrate reduction II (assimilatory)215
superpathway of fermentation (Chlamydomonas reinhardtii)717
Inorganic Nitrogen Assimilation414
superpathway of ammonia assimilation (plants)313
Organic Nitrogen Assimilation436
alkane oxidation212
oxalate degradation VI214
L-glutamine biosynthesis III725
cholesterol biosynthesis (plants)1417
glycine betaine biosynthesis III (plants)19
phytosterol biosynthesis (plants)1531
plant sterol biosynthesis II519
reductive TCA cycle I025
NAD salvage pathway V (PNC V cycle)017
cholesterol biosynthesis (plants, early side-chain reductase)117
glycerol degradation V08
N-hydroxy-L-pipecolate biosynthesis013
fluoroacetate and fluorothreonine biosynthesis016
Leishmania infection6626
Leishmania parasite growth and survival2018
Anti-inflammatory response favouring Leishmania parasite infection2018
FCGR3A-mediated IL10 synthesis79
Diseases of the neuronal system710
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
SARS-CoV Infections28229
SARS-CoV-1 Infection11422
Translation of Structural Proteins1114
Maturation of nucleoprotein45
SARS-CoV-1 Infection6019
SARS-CoV-2 Infection7720
SARS-CoV-2 Infection19527
Sensory Perception21568
Drug ADME6387
Azathioprine ADME1626
Late SARS-CoV-2 Infection Events3418
Cobalamin (Cbl) metabolism722
NADP biosynthesis05
GABA shunt II011
ketogenesis012
superpathway of L-serine and glycine biosynthesis I013
D-sorbitol degradation II05
aerobic respiration II (cytochrome c) (yeast)09
L-lysine degradation XI (mammalian)016
glycolysis III (from glucose)018
homolactic fermentation019
pyruvate fermentation to (R)-lactate05
arsenate detoxification V06
Bacterial Infection Pathways12347
Viral Infection Pathways72739
Parasitic Infection Pathways6626
Sulfatase and aromatase pathway1414
Glycosphingolipid catabolism1716
Sphingolipid catabolism814
guanosine nucleotides degradation416
gluconeogenesis2425
UDP-D-xylose and UDP-D-glucuronate biosynthesis28
NAD salvage47
NAD de novo biosynthesis1233
superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle4737
proline degradation113
sorbitol degradation I19
4-aminobutyrate degradation220
2-oxobutanoate degradation814
serine and glycine biosynthesis613
4-hydroxybenzoate biosynthesis119
oxidative ethanol degradation III715
adenosine nucleotides degradation818
superpathway of choline degradation to L-serine714
urate biosynthesis/inosine 5'-phosphate degradation612
taurine biosynthesis211
purine nucleotides degradation1129
leucine degradation1221
guanosine nucleotides de novo biosynthesis1518
purine nucleotides de novo biosynthesis3037
threonine degradation69
phenylalanine degradation/tyrosine biosynthesis415
valine degradation1320
isoleucine degradation1217
lactate fermentation (reoxidation of cytosolic NADH)35
D-glucuronate degradation212
lysine degradation II (pipecolate pathway)523
lysine degradation I (saccharopine pathway)431
u03B2-alanine degradation19
tryptophan degradation1345
tryptophan degradation via tryptamine416
L-kynurenine degradation1352
superpathway of tryptophan utilization4292
4-hydroxyproline degradation413
glycolysis2519
arachidonate biosynthesis III (metazoa)1619
TCA cycle1724
choline degradation27
malate-aspartate shuttle38
superpathway of methionine degradation1945
fatty acid u03B1-oxidation417
fatty acid u03B2-oxidation169
docosahexaenoate biosynthesis III (mammals)326
fatty acid u03B2-oxidation (peroxisome)1512
serine biosynthesis (phosphorylated route)411
NAD biosynthesis III (from nicotinamide)310
sulfoquinovose degradation I410
fumigaclavine biosynthesis420
NAD/NADP-NADH/NADPH mitochondrial interconversion (yeast)513
NAD/NADP-NADH/NADPH cytosolic interconversion (yeast)526
sulfoquinovose degradation II011
superpathway NAD/NADP - NADH/NADPH interconversion (yeast)1031
pyridine nucleotide cycling (plants)022
nitrate reduction VIIIb (dissimilatory)411
sulfoacetaldehyde degradation II16
NAD/NADH phosphorylation and dephosphorylation2919
NAD phosphorylation and transhydrogenation510
nitrate reduction VIII (dissimilatory)1915
(S,S)-butanediol degradation111
NAD phosphorylation and dephosphorylation312
(R,R)-butanediol degradation16
NADH to fumarate electron transfer1713
ethylene glycol degradation29
phytol degradation215
(S)-propane-1,2-diol degradation618
cyclohexanol degradation514
CMP-legionaminate biosynthesis I1026
methanol oxidation to carbon dioxide414
superpathway of glycol metabolism and degradation1035
alginate biosynthesis I (algal)210
alginate biosynthesis II (bacterial)89
2-oxoisovalerate decarboxylation to isobutanoyl-CoA49
pentachlorophenol degradation425
2-oxoglutarate decarboxylation to succinyl-CoA711
1,2-dichloroethane degradation115
L-homophenylalanine biosynthesis216
fluoroacetate and fluorothreonine biosynthesis422
u03B3-hexachlorocyclohexane degradation620
L-homomethionine biosynthesis420
4-methyl-proline biosynthesis114
3-hydroxy-L-homotyrosine biosynthesis516
allantoin degradation IV (anaerobic)422
vanillin and vanillate degradation II39
2-nitrobenzoate degradation I723
ammonia assimilation cycle I414
teichuronic acid biosynthesis (B. subtilis 168)1117
vanillin and vanillate degradation I28
superpathway of ammonia assimilation (plants)214
vancomycin resistance I514
L-tyrosine biosynthesis I616
hypotaurine degradation211
matairesinol biosynthesis220
superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis2257
mAGP1831
L-tyrosine biosynthesis III19
pyruvate decarboxylation to acetyl CoA79
justicidin B biosynthesis118
succinate fermentation to butanoate721
pyruvate fermentation to propanoate II (acrylate pathway)720
polymyxin resistance420
superpathway of acetyl-CoA biosynthesis212
L-glutamate degradation VII (to butanoate)1036
ethylene biosynthesis IV (engineered)218
pyruvate fermentation to propanoate I618
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle2459
protein S-nitrosylation and denitrosylation213
methyl ketone biosynthesis (engineered)413
glyoxylate cycle1336
formaldehyde oxidation I124
nitrate reduction II (assimilatory)415
ethylene glycol biosynthesis (engineered)615
superpathway of glyoxylate cycle and fatty acid degradation2625
O-antigen building blocks biosynthesis (E. coli)950
superpathway of glycolysis and the Entner-Doudoroff pathway2358
3-methylbutanol biosynthesis (engineered)918
(Z)-9-tricosene biosynthesis010
chitin degradation to ethanol1317
lactate biosynthesis (archaea)315
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass3989
methylaspartate cycle1035
colanic acid building blocks biosynthesis949
3-chlorotoluene degradation I57
enterobacterial common antigen biosynthesis1133
pyruvate fermentation to acetate and lactate I713
3-chlorotoluene degradation II39
2,3-dihydroxybenzoate degradation512
theophylline degradation315
retinoate biosynthesis II36
L-lysine biosynthesis V1424
salicortin biosynthesis020
L-lysine biosynthesis IV323
2-aminoethylphosphonate degradation II19
benzoate biosynthesis II (CoA-independent, non-u03B2-oxidative)013
retinoate biosynthesis I76
2-aminoethylphosphonate degradation I229
hydrogen oxidation II (aerobic, NAD)815
pyruvate fermentation to acetate and lactate II625
phosphatidate biosynthesis (yeast)919
iso-bile acids biosynthesis I29
pyruvate fermentation to acetate V312
pyruvate fermentation to acetate II611
acetone degradation III (to propane-1,2-diol)413
sphingosine and sphingosine-1-phosphate metabolism1120
1,2-dichlorobenzene degradation107
1,4-dichlorobenzene degradation919
1,2,4-trichlorobenzene degradation107
1,3-dichlorobenzene degradation57
1,2,4,5-tetrachlorobenzene degradation48
methanol oxidation to formaldehyde II17
chlorobenzene degradation67
arachidonate biosynthesis III (6-desaturase, mammals)519
glycine biosynthesis II610
L-tryptophan degradation V (side chain pathway)020
arachidonate biosynthesis I (6-desaturase, lower eukaryotes)413
L-tryptophan degradation IV (via indole-3-lactate)18
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase)527
TCA cycle I (prokaryotic)1741
NADH to cytochrome bd oxidase electron transfer II418
(R)- and (S)-3-hydroxybutanoate biosynthesis (engineered)717
TCA cycle VII (acetate-producers)219
NADH to cytochrome bo oxidase electron transfer II526
L-tryptophan degradation X (mammalian, via tryptamine)519
sulfoquinovosyl diacylglycerol biosynthesis58
photosynthetic 3-hydroxybutanoate biosynthesis (engineered)6373
TCA cycle II (plants and fungi)2422
L-tryptophan degradation VIII (to tryptophol)1213
L-glutamate degradation VIII (to propanoate)020
TCA cycle III (animals)1724
NADH to cytochrome bo oxidase electron transfer I1734
partial TCA cycle (obligate autotrophs)026
L-arabinose degradation IV814
3-hydroxypropanoate/4-hydroxybutanate cycle1840
NADH to cytochrome bd oxidase electron transfer I1627
salicylate glucosides biosynthesis II110
reductive acetyl coenzyme A pathway I (homoacetogenic bacteria)1322
L-arabinose degradation II58
vitamin B6 degradation1029
superpathway of pyrimidine deoxyribonucleosides degradation738
TCA cycle V (2-oxoglutarate:ferredoxin oxidoreductase)1233
formate oxidation to CO2417
superpathway of L-phenylalanine biosynthesis1665
superpathway of C1 compounds oxidation to CO22232
(+)-camphor biosynthesis112
aerobic respiration II (cytochrome c) (yeast)1911
TCA cycle IV (2-oxoglutarate decarboxylase)221
(-)-camphor biosynthesis010
wax esters biosynthesis II27
hypusine biosynthesis19
2-heptyl-3-hydroxy-4(1H)-quinolone biosynthesis319
aerobic respiration III (alternative oxidase pathway)3915
superpathway of methylglyoxal degradation1330
aerobic respiration I (cytochrome c)5015
UMP biosynthesis III1023
6-gingerol analog biosynthesis (engineered)420
propanoyl-CoA degradation II414
indican biosynthesis011
phenylacetate degradation I (aerobic)1530
phenylethylamine degradation I220
phenylethylamine degradation II710
dTDP-D-forosamine biosynthesis624
ethanol degradation II416
ethanol degradation I415
ethanol degradation III415
superpathway of ornithine degradation727
ethanol degradation IV415
ectoine degradation312
pyruvate fermentation to (R)-acetoin I39
L-lysine degradation II (L-pipecolate pathway)522
ethanolamine utilization1336
superpathway of L-lysine degradation33112
triethylamine degradation016
coenzyme M biosynthesis I528
histamine degradation424
pyruvate fermentation to (S)-acetoin29
u03B3-butyrobetaine degradation123
L-lysine degradation III126
abscisic acid biosynthesis813
superpathway of Clostridium acetobutylicum acidogenic and solventogenic fermentation1855
L-lysine degradation X219
dopamine degradation431
L-lysine degradation VIII113
aromatic biogenic amine degradation (bacteria)335
L-lysine degradation V133
L-lysine degradation XI (mammalian)531
superpathway of fermentation (Chlamydomonas reinhardtii)917
benzoyl-CoA degradation III (anaerobic)719
pyruvate fermentation to hexanol (engineered)819
benzoyl-CoA degradation I (aerobic)420
L-lysine degradation VI211
benzoyl-CoA degradation II (anaerobic)520
indigo biosynthesis09
limonene degradation I (D-limonene)326
superpathway of Clostridium acetobutylicum acidogenic fermentation1032
limonene degradation II (L-limonene)325
limonene degradation III (to perillate)110
pyruvate fermentation to isobutanol (engineered)1728
superpathway of Clostridium acetobutylicum solventogenic fermentation1444
L-tyrosine degradation V (Stickland reaction)314
mannojirimycin biosynthesis413
pyruvate fermentation to butanoate824
(R)-cysteate degradation210
dimethyl sulfoxide degradation06
L-tyrosine degradation III913
superpathway of sulfate assimilation and cysteine biosynthesis1241
zerumbone biosynthesis210
grixazone biosynthesis525
superpathway of quinolone and alkylquinolone biosynthesis724
shinorine biosynthesis321
dimethyl sulfone degradation06
ethanedisulfonate degradation07
3-sulfopropanediol degradation310
superpathway of dimethylsulfone degradation219
methanesulfonate degradation48
4,4'-disulfanediyldibutanoate degradation111
4-nitrotoluene degradation I310
3,3'-disulfanediyldipropannoate degradation517
4-nitrotoluene degradation II021
4-deoxy-L-threo-hex-4-enopyranuronate degradation1017
superpathway of microbial D-galacturonate and D-glucuronate degradation3592
dTDP-L-mycarose biosynthesis1118
2-nitrotoluene degradation312
Spodoptera littoralis pheromone biosynthesis032
L-glutamate and L-glutamine biosynthesis1442
nitrobenzene degradation II37
4-chloronitrobenzene degradation620
gadusol biosynthesis211
1-chloro-2-nitrobenzene degradation46
juvenile hormone III biosynthesis I422
2,4-dinitrotoluene degradation720
adenosine nucleotides degradation II1427
choline degradation IV211
2,6-dinitrotoluene degradation011
adenosine nucleotides degradation I227
choline-O-sulfate degradation416
2-oxobutanoate degradation I1028
purine nucleotides degradation I (plants)234
choline degradation I713
purine nucleotides degradation II (aerobic)2246
dTDP-N-acetylthomosamine biosynthesis618
juvenile hormone III biosynthesis II116
androgen biosynthesis715
inosine 5'-phosphate degradation1324
(8E,10E)-dodeca-8,10-dienol biosynthesis022
superpathway of purine deoxyribonucleosides degradation637
L-malate degradation I17
progesterone biosynthesis26
dTDP-D-ravidosamine and dTDP-4-acetyl-D-ravidosamine biosynthesis519
flavin biosynthesis II (archaea)828
flavin biosynthesis III (fungi)823
L-carnitine degradation III724
D-carnitine degradation I016
D-galactose detoxification523
D-carnitine degradation II011
L-carnitine degradation II124
dTDP-L-rhamnose biosynthesis1314
L-serine biosynthesis I1115
dTDP-6-deoxy-u03B1-D-allose biosynthesis610
superpathway of purine nucleotides de novo biosynthesis I3649
superpathway of guanosine nucleotides de novo biosynthesis I2436
biphenyl degradation212
u03B2 myrcene degradation39
dTDP-4-O-demethyl-u03B2-L-noviose biosynthesis515
2,2'-dihydroxybiphenyl degradation318
indole-3-acetate degradation216
methylsalicylate degradation19
L-alanine degradation IV418
1,8-cineole degradation012
L-alanine degradation II (to D-lactate)017
geraniol and nerol degradation011
propane degradation I915
dTDP-L-daunosamine biosynthesis616
4-hydroxyacetophenone degradation520
3-chlorobenzoate degradation I (via chlorocatechol)110
naphthalene degradation (aerobic)929
3-chlorobenzoate degradation II (via protocatechuate)512
diphenyl ethers degradation612
propane degradation II514
styrene degradation311
3-chlorobenzoate degradation III (via gentisate)09
reductive TCA cycle I327
p-cymene degradation1421
4-toluenecarboxylate degradation49
4-hydroxybenzoate biosynthesis III (plants)116
incomplete reductive TCA cycle618
superpathway of nicotinate degradation1254
4-hydroxybenzoate biosynthesis I (eukaryotes)414
orthanilate degradation014
3-methylquinoline degradation016
serotonin degradation721
dTDP-D-desosamine biosynthesis1422
5,5'-dehydrodivanillate degradation516
L-alanine fermentation to propanoate and acetate731
noradrenaline and adrenaline degradation823
reductive TCA cycle II1024
L-glutamate degradation V (via hydroxyglutarate)726
phthalate degradation (aerobic)19
2-propylphenol degradation311
L-lysine fermentation to acetate and butanoate857
Bifidobacterium shunt326
dibenzo-p-dioxin degradation011
4-hydroxymandelate degradation638
pinoresinol degradation07
hexitol fermentation to lactate, formate, ethanol and acetate736
4-amino-3-hydroxybenzoate degradation240
acetylene degradation121
noscapine biosynthesis1123
glycine betaine degradation I825
orcinol degradation020
methylglyoxal degradation VII09
terephthalate degradation410
anaerobic energy metabolism (invertebrates, mitochondrial)1342
superpathway of ergotamine biosynthesis728
superpathway of aromatic compound degradation via 2-hydroxypentadienoate5095
methylglyoxal degradation VI113
fermentation to 2-methylbutanoate018
p-cumate degradation1018
mixed acid fermentation3276
methylglyoxal degradation V215
(-)-dehydrodiconiferyl alcohol degradation517
alkane biosynthesis II114
p-cumate degradation to 2-hydroxypentadienoate813
superpathway of anaerobic energy metabolism (invertebrates)1660
enterobactin biosynthesis519
ethionamide activation014
4-hydroxyphenylacetate degradation825
methylglyoxal degradation IV221
purine nucleobases degradation I (anaerobic)240
p-cymene degradation to p-cumate39
crotonate fermentation (to acetate and cyclohexane carboxylate)327
diphenylamine degradation37
methylglyoxal degradation III78
purine nucleobases degradation II (anaerobic)051
isoniazid activation110
superpathway of aromatic compound degradation via 3-oxoadipate3681
benzoate fermentation (to acetate and cyclohexane carboxylate)330
2-isopropylphenol degradation311
anaerobic energy metabolism (invertebrates, cytosol)329
2-aminophenol degradation921
dibenzofuran degradation010
3-phenylpropanoate and 3-(3-hydroxyphenyl)propanoate degradation1122
2-hydroxybiphenyl degradation317
2-amino-3-carboxymuconate semialdehyde degradation to 2-hydroxypentadienoate411
superpathway of salicylate degradation617
2-hydroxypenta-2,4-dienoate degradation915
juglone degradation011
naphthalene degradation to acetyl-CoA1138
D-erythronate degradation I110
benzene degradation411
m-cresol degradation116
acrylate degradation411
2,5-xylenol and 3,5-xylenol degradation427
UDP-sugars interconversion1234
glutaryl-CoA degradation314
D-erythronate degradation II411
N10-formyl-tetrahydrofolate biosynthesis1256
aniline degradation516
ethylbenzene degradation (anaerobic)1124
2-amino-3-carboxymuconate semialdehyde degradation to glutaryl-CoA226
glycine betaine biosynthesis III (plants)29
D-malate degradation17
glycine betaine biosynthesis II (Gram-positive bacteria)210
mevalonate degradation212
glycine betaine biosynthesis I (Gram-negative bacteria)221
L-threonate degradation411
dehydro-D-arabinono-1,4-lactone biosynthesis39
superpathway of N-acetylneuraminate degradation3979
D-threonate degradation110
nicotine degradation II (pyrrolidine pathway)1034
nicotine degradation III (VPP pathway)1032
nicotine degradation I (pyridine pathway)1341
L-leucine degradation III812
paromamine biosynthesis I1020
L-leucine degradation IV (Stickland reaction)313
(S,S)-butanediol biosynthesis111
meso-butanediol biosynthesis I26
factor 430 biosynthesis620
L-leucine degradation I2026
superpathway of (R,R)-butanediol biosynthesis415
paromamine biosynthesis II522
meso-butanediol biosynthesis II15
(R,R)-butanediol biosynthesis16
superpathway of 2,3-butanediol biosynthesis723
L-aspartate degradation II513
butanol and isobutanol biosynthesis (engineered)1320
glycerol degradation to butanol1035
1,2-propanediol biosynthesis from lactate (engineered)316
nicotinate degradation III1241
pyruvate fermentation to butanol II (engineered)615
glycerol degradation III613
nicotinate degradation I833
1,3-propanediol biosynthesis (engineered)1535
1-butanol autotrophic biosynthesis (engineered)4938
pyruvate fermentation to butanol I1125
vibriobactin biosynthesis618
glutathione amide metabolism011
coenzyme B biosynthesis331
L-phenylalanine degradation I (aerobic)515
GDP-6-deoxy-D-altro-heptose biosynthesis410
guanosine ribonucleotides de novo biosynthesis1535
L-phenylalanine degradation VI (Stickland reaction)316
folate transformations II521
superpathway of purine nucleotide salvage1334
folate transformations I2241
L-phenylalanine degradation III1213
aliphatic glucosinolate biosynthesis, side chain elongation cycle340
GDP-L-galactose biosynthesis212
L-phenylalanine degradation IV (mammalian, via side chain)639
rebeccamycin biosynthesis723
glycine cleavage910
L-phenylalanine degradation II (anaerobic)512
kanamycin biosynthesis1042
superpathway of thiamine diphosphate biosynthesis III (eukaryotes)1225
superpathway of rifamycin B biosynthesis1354
NADH to hydrogen peroxide electron transfer146
staphyloferrin B biosynthesis720
guaiacylglycerol-u03B2-guaiacyl ether degradation615
pentalenolactone biosynthesis723
D-xylose degradation V414
novobiocin biosynthesis1741
validamycin biosynthesis1034
fatty acid u03B2-oxidation II (peroxisome)912
fatty acid u03B1-oxidation II718
fatty acid u03B2-oxidation I2316
pyocyanin biosynthesis212
10-trans-heptadecenoyl-CoA degradation (MFE-dependent, yeast)215
fosfomycin biosynthesis426
formaldehyde assimilation III (dihydroxyacetone cycle)422
caffeine degradation V (bacteria, via trimethylurate)119
fatty acid u03B2-oxidation (peroxisome, yeast)413
formaldehyde assimilation I (serine pathway)944
dapdiamides biosynthesis831
caffeine degradation IV (bacteria, via demethylation and oxidation)016
fatty acid u03B1-oxidation III312
fatty acid u03B1-oxidation I17
K-252 biosynthesis020
caffeine degradation III (bacteria, via demethylation)521
glycerol-3-phosphate shuttle410
9-cis, 11-trans-octadecadienoyl-CoA degradation (isomerase-dependent, yeast)419
D-xylose degradation IV815
L-histidine degradation II522
10-cis-heptadecenoyl-CoA degradation (yeast)523
L-histidine degradation I414
ketogenesis614
oleate u03B2-oxidation (isomerase-dependent, yeast)213
fatty acid u03B2-oxidation VI (peroxisome)1412
L-histidine degradation V19
alkane oxidation48
ketolysis412
10-trans-heptadecenoyl-CoA degradation (reductase-dependent, yeast)523
L-pyrrolysine biosynthesis313
neopentalenoketolactone and pentalenate biosynthesis725
streptomycin biosynthesis452
erythritol degradation II310
taurine biosynthesis II219
phosalacine biosynthesis2049
myo-, chiro- and scyllo-inositol degradation921
gluconeogenesis III2425
D-sorbitol degradation I512
gluconeogenesis I2862
superpathway of hexitol degradation (bacteria)2960
taurine biosynthesis I420
superpathway of CDP-glucose-derived O-antigen building blocks biosynthesis922
D-altritol and galactitol degradation410
myo-inositol degradation II511
bacilysin biosynthesis620
CDP-4-dehydro-3,6-dideoxy-D-glucose biosynthesis415
myo-inositol degradation I921
xylitol degradation612
ribitol degradation114
D-arabitol degradation08
D-threitol degradation310
L-leucine biosynthesis719
mannitol cycle315
L-histidine biosynthesis1833
mannitol degradation I15
D-sorbitol degradation II210
staurosporine biosynthesis824
galactitol degradation913
L-threitol degradation411
D-galactose degradation IV59
D-galactose degradation II28
phosphinothricin tripeptide biosynthesis1956
oxalate degradation VI414
D-galactose degradation V (Leloir pathway)813
D-galactose degradation I (Leloir pathway)1046
oxalate degradation III223
4-aminobutanoate degradation V318
indolmycin biosynthesis830
L-threonine degradation IV415
salicylate degradation IV315
4-aminobutanoate degradation IV410
superpathway of 4-aminobutanoate degradation520
4-aminobutanoate degradation I720
puromycin biosynthesis227
GABA shunt623
salicylate degradation I39
kanosamine biosynthesis II310
u03B3-resorcylate degradation II411
L-cysteine biosynthesis IX (Trichomonas vaginalis)514
dehydrophos biosynthesis1025
kanosamine biosynthesis I211
L-threonine degradation II331
salicylate degradation II27
L-threonine degradation V69
L-threonine degradation III (to methylglyoxal)328
L-proline degradation715
jasmonic acid biosynthesis734
superpathway of lipoxygenase1632
traumatin and (Z)-3-hexen-1-yl acetate biosynthesis820
urate conversion to allantoin II412
L-isoleucine degradation I1520
L-isoleucine degradation II1212
benzoate degradation I (aerobic)510
meta cleavage pathway of aromatic compounds1422
icosapentaenoate biosynthesis V (8-desaturase, lower eukaryotes)513
ursodeoxycholate biosynthesis (bacteria)18
icosapentaenoate biosynthesis III (8-desaturase, mammals)419
superpathway of L-serine and glycine biosynthesis I920
glycolate and glyoxylate degradation I726
superpathway of branched chain amino acid biosynthesis1143
superpathway of aromatic amino acid biosynthesis2184
fluorene degradation II09
fluorene degradation I015
Methanobacterium thermoautotrophicum biosynthetic metabolism2279
1,4-dimethylbenzene degradation to 4-methylbenzoate39
protocatechuate degradation III (para-cleavage pathway)515
1,3-dimethylbenzene degradation to 3-methylbenzoate39
L-valine degradation I1727
D-glucuronate degradation I221
dimethyl sulfide degradation I217
D-glucuronate degradation II317
L-valine degradation II1112
superpathway of u03B2-D-glucuronosides degradation1136
cob(II)yrinate a,c-diamide biosynthesis II (late cobalt incorporation)1444
cob(II)yrinate a,c-diamide biosynthesis I (early cobalt insertion)1731
4-nitrophenol degradation II713
neurosporaxanthin biosynthesis314
superpathway of cholesterol degradation II (cholesterol dehydrogenase)3058
4-nitrophenol degradation I916
superpathway of cholesterol degradation I (cholesterol oxidase)1755
cholesterol degradation to androstenedione I (cholesterol oxidase)1931
diadinoxanthin and fucoxanthin biosynthesis013
cholesterol degradation to androstenedione II (cholesterol dehydrogenase)1334
cinnamate and 3-hydroxycinnamate degradation to 2-hydroxypentadienoate812
salinosporamide A biosynthesis1129
3-phenylpropanoate degradation124
bisphenol A degradation114
superpathway of phenylethylamine degradation939
echinenone and zeaxanthin biosynthesis (Synechocystis)112
2,2'-dihydroxyketocarotenoids biosynthesis214
3-phenylpropanoate and 3-(3-hydroxyphenyl)propanoate degradation to 2-hydroxypentadienoate815
chorismate biosynthesis I1559
chorismate biosynthesis II (archaea)930
nostoxanthin biosynthesis38
tRNA splicing I712
N-methylpyrrolidone degradation415
formaldehyde oxidation III (mycothiol-dependent)29
formaldehyde oxidation V (bacillithiol-dependent)19
formaldehyde oxidation IV (thiol-independent)08
u03B2-alanine degradation I011
carbon disulfide oxidation II (aerobic)09
u03B2-alanine degradation II012
L-glutamate biosynthesis IV110
coelimycin P1 biosynthesis427
L-ornithine degradation I (L-proline biosynthesis)27
L-dopa degradation117
glycolysis II (from fructose 6-phosphate)2149
flaviolin dimer and mompain biosynthesis622
glycolysis I (from glucose 6-phosphate)3751
glycolysis IV (plant cytosol)747
L-lactaldehyde degradation (anaerobic)29
glycolysis III (from glucose)3725
L-lactaldehyde degradation (aerobic)411
L-ascorbate degradation II (bacterial, aerobic)419
catechol degradation to 2-hydroxypentadienoate II412
L-ascorbate degradation IV113
L-rhamnose degradation II623
catechol degradation II (meta-cleavage pathway)819
L-rhamnose degradation III311
catechol degradation I (meta-cleavage pathway)817
superpathway of bacteriochlorophyll a biosynthesis2270
guanosine nucleotides degradation III1425
pyruvate fermentation to lactate420
bacteriochlorophyll b biosynthesis620
toluene degradation I (aerobic) (via o-cresol)517
bacteriochlorophyll a biosynthesis1124
siroheme biosynthesis811
abietic acid biosynthesis416
bile acids degradation940
glycocholate metabolism (bacteria)424
superpathway of dTDP-glucose-derived antibiotic building blocks biosynthesis3139
androstenedione degradation3439
superpathway of diterpene resin acids biosynthesis443
sitosterol degradation to androstenedione033
superpathway of testosterone and androsterone degradation1136
superpathway of erythromycin biosynthesis1842
superpathway of dTDP-glucose-derived O-antigen building blocks biosynthesis2836
L-tryptophan degradation IX026
UDP-u03B1-D-xylose biosynthesis821
the visual cycle I (vertebrates)1410
superpathway of L-tyrosine biosynthesis1557
toluene degradation VI (anaerobic)1838
L-tryptophan degradation XIII (Stickland reaction)312
2,4-xylenol degradation to protocatechuate317
putrescine degradation IV419
UDP-N-acetyl-D-galactosamine biosynthesis I43
toluene degradation to 4-methylphenol67
putrescine degradation V210
toluene degradation to benzoyl-CoA (anaerobic)1319
putrescine degradation I310
superpathway of vanillin and vanillate degradation827
menaquinol-4 biosynthesis II110
toluene degradation to benzoate511
L-arginine degradation VIII (arginine oxidase pathway)325
toluene degradation III (aerobic) (via p-cresol)924
toluene degradation to 2-hydroxypentadienoate I (via o-cresol)512
putrescine degradation III316
L-arginine degradation (Stickland reaction)1254
superpathway of L-arginine, putrescine, and 4-aminobutanoate degradation1242
UDP-yelosamine biosynthesis214
superpathway of chorismate metabolism56186
L-arginine degradation I (arginase pathway)831
L-arginine degradation II (AST pathway)822
UDP-u03B1-D-glucuronate biosynthesis (from UDP-glucose)56
sucrose biosynthesis I (from photosynthesis)1326
toluene degradation to 2-hydroxypentadienoate (via toluene-cis-diol)513
L-arginine degradation VII (arginase 3 pathway)210
L-arginine degradation IX (arginine:pyruvate transaminase pathway)215
UDP-u03B1-D-galactose biosynthesis418
toluene degradation IV (aerobic) (via catechol)1625
toluene degradation to 2-hydroxypentadienoate (via 4-methylcatechol)711
superpathway of L-arginine and L-ornithine degradation1347
L-glutamate degradation IV620
L-glutamate degradation I333
UDP-N-acetyl-u03B1-D-galactosaminuronate biosynthesis27
UDP-N-acetyl-u03B1-D-mannosaminouronate biosynthesis310
UDP-N-acetyl-u03B1-D-quinovosamine biosynthesis36
Entner-Doudoroff pathway I1639
UDP-N-acetyl-u03B1-D-fucosamine biosynthesis26
superpathway of fucose and rhamnose degradation1141
Entner-Doudoroff pathway III (semi-phosphorylative)228
superpathway of C28 brassinosteroid biosynthesis737
mandelate degradation I414
mandelate degradation to acetyl-CoA1233
L-malate degradation II16
superpathway of coenzyme A biosynthesis II (plants)532
UDP-2,3-diacetamido-2,3-dideoxy-u03B1-D-mannuronate biosynthesis516
UDP-N,N'-diacetylbacillosamine biosynthesis612
L-tryptophan degradation III (eukaryotic)1745
L-tryptophan degradation XII (Geobacillus)326
UDP-D-apiose biosynthesis (from UDP-D-glucuronate)116
UDP-u03B1-D-galacturonate biosynthesis I (from UDP-D-glucuronate)211
L-ascorbate biosynthesis I (L-galactose pathway)923
3,4-dichlorotoluene degradation513
2,4-dichlorotoluene degradation516
L-ascorbate biosynthesis V127
homolactic fermentation3423
2,5-dichlorotoluene degradation514
L-ascorbate biosynthesis II (L-gulose pathway)012
heterolactic fermentation737
UDP-u03B2-L-rhamnose biosynthesis412
toluene degradation II (aerobic) (via 4-methylcatechol)716
glycerol degradation V416
glycerol degradation II318
superpathway of glycerol degradation to 1,3-propanediol826
aspartate superpathway25122
superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis1139
Fe(II) oxidation911
iron reduction and absorption54
aminopropanol phosphate biosynthesis II328
hydrogen production II35
toluene degradation V (aerobic) (via toluene-cis-diol)718
D-galacturonate degradation I527
D-galacturonate degradation II426
hydrogen production I37
L-galactonate degradation26
D-fructuronate degradation829
superpathway of hydrogen production35
L-gulonate degradation15
superpathway of hexuronide and hexuronate degradation838
quinate degradation II69
(4S)-carveol and (4S)-dihydrocarveol degradation231
(4R)-carveol and (4R)-dihydrocarveol degradation231
plant sterol biosynthesis1652
pyridoxal 5'-phosphate biosynthesis I726
superpathway of L-tryptophan biosynthesis1665
pyruvate fermentation to opines622
dimethylsulfoniopropanoate biosynthesis II (Spartina)022
staphyloxanthin biosynthesis421
superpathway of purines degradation in plants645
dimethylsulfoniopropanoate biosynthesis I (Wollastonia)113
superpathway of L-threonine metabolism2172
L-carnitine biosynthesis623
2-chlorobenzoate degradation38
superpathway of anaerobic sucrose degradation2661
brassinosteroid biosynthesis I829
brassinosteroid biosynthesis II522
trans-4-hydroxy-L-proline degradation I425
superpathway of aerobic toluene degradation3847
D-arabinose degradation I419
superpathway of glyoxylate bypass and TCA1855
superpathway of pyridoxal 5'-phosphate biosynthesis and salvage937
isoprene degradation817
L-sorbose degradation06
2-methylpropene degradation018
melibiose degradation114
propene degradation1018
2,4,5-trichlorophenoxyacetate degradation622
superpathway of UDP-N-acetylglucosamine-derived O-antigen building blocks biosynthesis2461
ethene and chloroethene degradation521
chlorosalicylate degradation317
methyl tert-butyl ether degradation1425
L-glucose degradation017
butane degradation816
photorespiration1723
acetoin degradation47
VTC2 cycle213
mannitol degradation II115
chitobiose degradation28
L-tryptophan degradation XI (mammalian, via kynurenine)1356
3,6-anhydro-u03B1-L-galactopyranose degradation515
2'-deoxy-u03B1-D-ribose 1-phosphate degradation428
docosahexaenoate biosynthesis III (6-desaturase, mammals)527
superpathway of glucose and xylose degradation029
extended VTC2 cycle213
superpathway of pentose and pentitol degradation4661
shikimate degradation II27
sulfolactate degradation I410
4-toluenesulfonate degradation II06
4-toluenesulfonate degradation I614
L-methionine degradation III811
benzenesulfonate degradation06
superpathway of L-methionine salvage and degradation2869
pyruvate fermentation to ethanol II911
ethylene biosynthesis II (microbes)119
ethylene biosynthesis III (microbes)015
pyruvate fermentation to ethanol III210
thiazole biosynthesis III (eukaryotes)29
pyruvate fermentation to ethanol I1020
3-dehydroquinate biosynthesis II (archaea)623
3-dehydroquinate biosynthesis I531
L-isoleucine biosynthesis II1430
phenylethanol biosynthesis815
NADH to trimethylamine N-oxide electron transfer158
NAD salvage pathway I (PNC VI cycle)420
2,3-dihydroxybenzoate biosynthesis910
NAD salvage pathway II (PNC IV cycle)314
ascorbate recycling (cytosolic)512
NAD de novo biosynthesis II (from tryptophan)1835
terrequinone A biosynthesis418
NAD de novo biosynthesis I (from aspartate)734
chanoclavine I aldehyde biosynthesis716
3-dimethylallyl-4-hydroxybenzoate biosynthesis314
NAD salvage pathway IV (from nicotinamide riboside)88
superpathway of NAD biosynthesis in eukaryotes1135
NAD salvage pathway III (to nicotinamide riboside)213
NAD salvage pathway V (PNC V cycle)421
NADH to dimethyl sulfoxide electron transfer168
NAD biosynthesis from 2-amino-3-carboxymuconate semialdehyde816
galactose degradation I (Leloir pathway)526
superpathway of serine and glycine biosynthesis I613
superpathway of leucine, valine, and isoleucine biosynthesis931
aspartate degradation II59
leucine biosynthesis516
folate transformations1219
histidine biosynthesis722
glycerol biosynthesis412
ethylene biosynthesis815
glutamate biosynthesis from glutamine16
superpathway of thiamin diphosphate biosynthesis III (eukaryotes)2541
serine biosynthesis from 3-phosphoglycerate411
superpathway NAD/NADP - NADH/NADPH interconversion1129
folate interconversions1317
tRNA splicing812
nicotinamide riboside salvage pathway I37
NAD salvage pathway1121
NAD/NADP-NADH/NADPH cytosolic interconversion626
NAD/NADP-NADH/NADPH mitochondrial interconversion713
tryptophan degradation VIII (to tryptophol)1213
phenylalanine degradation1112
isoleucine degradation II1312
leucine degradation III912
aerobic respiration (cytochrome c)3613
aerobic respiration (linear view)3613
(R)-acetoin biosynthesis I38
superpathway of acetoin and butanediol biosynthesis49
butanediol biosynthesis16
superpathway phosphatidate biosynthesis (yeast)1019
periplasmic NAD degradation17
fatty acid oxidation (non-cyclic)913
10-trans-heptadecenoyl-CoA degradation (reductase-dependent)523
10-trans-heptadecenoyl-CoA degradation (MFE-dependent)215
9-cis, 11-trans-octadecadienoyl-CoA degradation (isomerase-dependent)419
10-cis-heptadecenoyl-CoA degradation523
oleate u03B2-oxidation (isomerase-dependent)213
2-ketoglutarate dehydrogenase complex37
glutamate degradation to 2-oxoglutarate17
pyruvate dehydrogenase complex47
sorbitol degradation49
L-serine biosynthesis611
D-galactose degradation III419
TCA cycle variation V (plant)2325
malate-oxaloacetate shuttle I65
NAD biosynthesis I (from aspartate)420
superpathway of proto- and siroheme biosynthesis1640
plant sterol biosynthesis II1231
lysine degradation II221
brassinosteroid biosynthesis III110
succinic fermentation pathway012
superpathway of sterol biosynthesis050
superpathway of central carbon metabolism346
respiration (anaerobic)026
glycolysis I118
biopterin metabolism013
folate metabolism022
NAD biosynthesis II (from tryptophan)024
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
serine biosynthesis011
glycerolipid biosynthesis - initial steps010
superpathway of phospholipid biosynthesis027
superpathway of glycolysis, pyruvate dehydrogenase and TCA cycle134
oxaloacetate degradation to pyruvate09
ethanol degradation II (cytosol)012
glycerol metabolism011
leucine degradation I020
valine degradation I018
glycine cleavage complex08
3-phenylpropanoate and 3-(3-hydroxyphenyl)propanoate degradation to 2-oxopent-4-enoate013
superpathway of phenylalanine, tyrosine, and tryptophan biosynthesis038
NAD salvage pathway I018
glycolysis I (from glucose-6P)018
glycolysis II (from fructose-6P)017
superpathway of u03B2-D-glucuronide and D-glucuronate degradation014
tyrosine biosynthesis I09
superpathway of tyrosine biosynthesis024
phenylalanine degradation I (aerobic)010
folate transformations II (plants)424
TCA cycle variation I719
aerobic respiration -- electron donors reaction list314
phenylalanine degradation III112
glutamate degradation V (via hydroxyglutarate)116
glycine degradation I114
glutamate biosynthesis IV16
branched-chain u03B1-keto acid dehydrogenase complex37
ethanol fermentation to acetate119
superpathway of phenylalanine and tyrosine biosynthesis113
lysine fermentation to acetate and butyrate021
glutamate degradation I17
glutamate degradation VII (to butanoate)125
aerobic respiration -- electron donor III29
2-methylbutyrate biosynthesis015
acetyl-CoA biosynthesis (from pyruvate)37
NAD salvage pathway III07
4-aminobutyrate degradation V217
superpathway of chorismate576
NAD salvage pathway II110
mycolyl-arabinogalactan-peptidoglycan complex biosynthesis2131
superpathway of branched amino acid biosynthesis931
superpathway of phosphatidate biosynthesis (yeast)212
2-oxopentenoate degradation710
alanine degradation IV17
glucose and xylose degradation2328
cinnamate and 3-hydroxycinnamate degradation to 2-oxopent-4-enoate112
NAD phosphorylation and dephosphorylation I28
formylTHF biosynthesis1126
3-phenylpropionate and 3-(3-hydroxyphenyl)propionate degradation1217
NADH to cytochrome bo oxidase electron transfer167
NADH to cytochrome bd oxidase electron transfer147
5-dehydro-4-deoxy-D-glucuronate degradation411
arginine degradation II (AST pathway)616
pantothenate and coenzyme A biosynthesis II434
tyrosine biosynthesis III29
myo-, chiro- and scillo-inositol degradation617
superpathway of purine nucleotides de novo biosynthesis II2638
superpathway of guanosine nucleotides de novo biosynthesis II417
arginine, ornithine and proline interconversion725
proline degradation III37
tryptophan degradation III (eukaryotic)1029
4-hydroxyproline degradation I413
Fe(III)-reduction and Fe(II) transport15
TCA cycle variation III (eukaryotic)1220
ketone oxidation710
Leucine Catabolism1221
4-aminobutyrate degradation IV29
Serine degradation II410
glutamate degradation IV413
NAD biosynthesis III47
L-ascorbate biosynthesis VI519
glutamate degradation III (via 4-aminobutyrate)410
bile acid biosynthesis, neutral pathway644
alanine degradation II (to D-lactate)010
superpathway of leucine, valine, alanine, and isoleucine biosynthesis033
superpathway of glycolysis and TCA variant VIII033
fatty acid oxidation pathway I011
L-arabinose degradation IIIb012
adenosylcobalamin biosynthesis II (aerobic)060
superpathway of carotenoid biosynthesis029
valine degradation III021
leucine degradation IV023
respiration (anaerobic)-- electron acceptors reaction list021
L-cysteine degradation IV013
isoleucine degradation III017
transulfuration021
respiration (anaerobic)-- electron donors reaction list014
tetrahydrotyrosine biosynthesis47
2-methylbutanoate biosynthesis014
methionine degradation III1210
tyrosine degradation III1212
valine degradation II2110
4-hydroxybenzoate biosynthesis I (animals)315
lysine biosynthesis IV420
purine nucleotides degradation III (anaerobic)627
purine nucleotides degradation IV (anaerobic)1035
urate biosynthesis410
adenosylcobalamin biosynthesis II (late cobalt incorporation)2655
sulfoglycolysis410
(S)-acetoin biosynthesis08
aerobic respiration (alternative oxidase pathway)09
myo-inositol degradation014
2-amino-3-carboxymuconate semialdehyde degradation to 2-oxopentenoate011
D-chiro-inositol degradation012
L-1,2-propanediol degradation013
glycolysis III (glucokinase)017
acetyl-CoA biosynthesis I (pyruvate dehydrogenase complex)07
3-hydroxypropionate/4-hydroxybutyrate cycle029
dimethylsulfoniopropionate biosynthesis II (Spartina)015
galactose degradation IV013
phenylalanine degradation IV (mammalian, via side chain)026
ornithine degradation II (Stickland reaction)019
TCA cycle VI (obligate autotrophs)027
4-hydroxybenzoate biosynthesis V015
tryptophan degradation X (mammalian, via tryptamine)015
dimethylsulfoniopropionate biosynthesis I (Wollastonia)011
glutamine biosynthesis III024
lysine degradation VIII08
glutamate and glutamine biosynthesis012
pyruvate fermentation to propionate II (acrylate pathway)010
NADH to cytochrome bd oxidase electron transport II137
glycolysis VI (metazoan)1818
4-coumarate degradation414
superpathway of aromatic compound degradation3349
Mevalonate arm of cholesterol biosynthesis pathway1321
Alternative pathway of fetal androgen synthesis717
pyruvate dehydrogenase complex09
TCA cycle (plant)721
Beta-alanine biosynthesis II118
Arginine degradation412
Glutamate biosynthesis IV06
Histidine biosynthesis I721
Leucine biosynthesis015
Lysine biosynthesis II226
Glycine betaine biosynthesis08
GABA shunt110
Lysine degradation II318
Ehrlich pathway011
threonine catabolism114
Proline degradation18
Valine degradation817
glycolysis IV119
UDPXyl biosynthesis07
UDP-L-arabinose biosynthesis and transport616
Galactose degradation II015
Ascorbate biosynthesis417
NAD biosynthesis I (from aspartate)419
Pyridoxal 5'-phosphate biosynthesis020
ABA biosynthesis and mediated signaling315
ABA synthesis112
Abscisic acid homeostasis216
phospholipid biosynthesis411
Glutamate synthase cycle310
Nitrate assimilation012
ureide biogenesis417
PCO cycle824
Lipid metabolism321
The tricarboxylic acid cycle422
Purine metabolism938
De novo synthesis of GMP112
Urate synthesis211
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence19
Metabolic Epileptic Disorders2589
NAD biosynthesis I from aspartate020
NAD salvage pathway I017
NAD salvage pathway II011
Tryptophan degradation07
TCA cycle (Krebs cycle)3019
NAD biosynthesis II from tryptophan024
Vitamin B12 metabolism050
Glycerophospholipid biosynthetic pathway3233
Methionine de novo and salvage pathway148
NAD metabolism, sirtuins and aging03
NAD+ metabolism014
NAD+ biosynthetic pathways014
Oxidative phosphorylation05
Glucuronidation014
TCA cycle (aka Krebs or citric acid cycle)024

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency7.16690.000221.22318,912.5098AID743042
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency10.12350.001723.839378.1014AID743083
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Exotoxin APseudomonas aeruginosaKd59.566735.000059.566780.0000AID977611
Chain B, Exotoxin APseudomonas aeruginosaKd59.566735.000059.566780.0000AID977611
Chain B, Exotoxin APseudomonas aeruginosaKd59.566735.000059.566780.0000AID977611
2-dehydropantoate 2-reductaseEscherichia coli K-12Kd6,900.00000.26000.26000.2600AID269136
C-terminal-binding protein 1Homo sapiens (human)Kd2.21290.39002.21297.9000AID1802396
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
L-lactate dehydrogenase B chainSus scrofa (pig)Km84.40007.00007.00007.0000AID99370
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)Km80.00009.00009.00009.0000AID597364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
glutamate catabolic processGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
glutamine metabolic processGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
tricarboxylic acid metabolic processGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
pantothenate biosynthetic process2-dehydropantoate 2-reductaseEscherichia coli K-12
pantothenate biosynthetic process2-dehydropantoate 2-reductaseEscherichia coli K-12
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
protein phosphorylationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 1Homo sapiens (human)
viral genome replicationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle endocytosisC-terminal-binding protein 1Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 1Homo sapiens (human)
regulation of cell cycleC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle clusteringC-terminal-binding protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
glutamate dehydrogenase (NAD+) activityGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
glutamate dehydrogenase [NAD(P)+] activityGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
glutamate dehydrogenase (NADP+) activityGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
ATP bindingGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
GTP bindingGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
identical protein bindingGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
2-dehydropantoate 2-reductase activity2-dehydropantoate 2-reductaseEscherichia coli K-12
oxidoreductase activity2-dehydropantoate 2-reductaseEscherichia coli K-12
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor2-dehydropantoate 2-reductaseEscherichia coli K-12
NADP binding2-dehydropantoate 2-reductaseEscherichia coli K-12
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleic acid bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
transcription corepressor bindingC-terminal-binding protein 1Homo sapiens (human)
chromatin bindingC-terminal-binding protein 1Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 1Homo sapiens (human)
protein bindingC-terminal-binding protein 1Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 1Homo sapiens (human)
protein domain specific bindingC-terminal-binding protein 1Homo sapiens (human)
identical protein bindingC-terminal-binding protein 1Homo sapiens (human)
NAD bindingC-terminal-binding protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 1Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
mitochondrionGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
mitochondrial inner membraneGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
endoplasmic reticulumGlutamate dehydrogenase 1, mitochondrial Bos taurus (cattle)
cytoplasm2-dehydropantoate 2-reductaseEscherichia coli K-12
cytoplasm2-dehydropantoate 2-reductaseEscherichia coli K-12
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
azurophil granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusC-terminal-binding protein 1Homo sapiens (human)
nucleoplasmC-terminal-binding protein 1Homo sapiens (human)
presynaptic active zone cytoplasmic componentC-terminal-binding protein 1Homo sapiens (human)
glutamatergic synapseC-terminal-binding protein 1Homo sapiens (human)
GABA-ergic synapseC-terminal-binding protein 1Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 1Homo sapiens (human)
nucleusC-terminal-binding protein 1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008EMBO reports, Aug, Volume: 9, Issue:8
The nature and character of the transition state for the ADP-ribosyltransferase reaction.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2001Science (New York, N.Y.), Aug-17, Volume: 293, Issue:5533
Immunocyte Ca2+ influx system mediated by LTRPC2.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2003The Biochemical journal, May-01, Volume: 371, Issue:Pt 3
Expression profile of the transient receptor potential (TRP) family in neutrophil granulocytes: evidence for currents through long TRP channel 2 induced by ADP-ribose and NAD.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2002Molecular cell, Jan, Volume: 9, Issue:1
LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2006The EMBO journal, May-03, Volume: 25, Issue:9
TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion.
AID1346335Human P2Y11 receptor (P2Y receptors)2006The Journal of biological chemistry, Oct-20, Volume: 281, Issue:42
Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID33708Michaelis-Menten constant against mammalian liver alcohol dehydrogenase (ADH)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
CNAD: a potent and specific inhibitor of alcohol dehydrogenase.
AID597365Activity at yeast SIRT2 assessed as ADP-ribosyltransferase activity2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD).
AID74665In vitro inhibitory activity against bovine liver glutamate dehydrogenase (GDH)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Dehydrogenase binding by tiazofurin anabolites.
AID106792In vitro inhibitory activity against pig heart cytoplasmic malate dehydrogenase (MDH),1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Dehydrogenase binding by tiazofurin anabolites.
AID74666Michaelis-Menten constant against mammalian glutamate dehydrogenase (GDH)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
CNAD: a potent and specific inhibitor of alcohol dehydrogenase.
AID70969Tested by protection experiments to demonstrate the inactivation of estradiol dehydrogenase and the kinetic parameter Kapp was reported at a concentration of 20 uM1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Trifluoromethylacetylenic alcohols as affinity labels: inactivation of estradiol dehydrogenase by a trifluoromethylacetylenic secostradiol.
AID268956Inhibition of human IMPDH2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase.
AID269136Binding affinity to Escherichia coli KPR2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.
AID597364Activity at human SIRT1 assessed as ADP-ribosyltransferase activity2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD).
AID99370In vitro inhibitory activity against pig heart lactate dehydrogenase (LDH)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Dehydrogenase binding by tiazofurin anabolites.
AID269134Inhibition of Escherichia coli KPR at 20 mM2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.
AID33861In vitro inhibitory activity against horse liver Alcohol dehydrogenase1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Dehydrogenase binding by tiazofurin anabolites.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID106795Michaelis-Menten constant against mammalian malate dehydrogenase (MDH)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
CNAD: a potent and specific inhibitor of alcohol dehydrogenase.
AID99367Michaelis-Menten constant against mammalian lactate dehydrogenase (LDH)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
CNAD: a potent and specific inhibitor of alcohol dehydrogenase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID52125Compound was tested for inhibition of choline acetyltransferase isolated from squid head ganglia; No inhibition at 10e-4 M1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Interaction of aromatic dyes with the coenzyme A binding site of choline acetyltransferase.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1802396Equilibrium Dialysis from Article 10.1074/jbc.M113.493569: \\Nicotinamide adenine dinucleotide-induced multimerization of the co-repressor CtBP1 relies on a switching tryptophan.\\2013The Journal of biological chemistry, Sep-27, Volume: 288, Issue:39
Nicotinamide adenine dinucleotide-induced multimerization of the co-repressor CtBP1 relies on a switching tryptophan.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28,871)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015312 (53.04)18.7374
1990's3819 (13.23)18.2507
2000's3729 (12.92)29.6817
2010's4031 (13.96)24.3611
2020's1980 (6.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 91.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index91.78 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index240.41 (26.88)
Search Engine Supply Index3.02 (0.95)

This Compound (91.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials88 (0.29%)5.53%
Trials0 (0.00%)5.53%
Reviews1,582 (5.25%)6.00%
Reviews1 (4.76%)6.00%
Case Studies77 (0.26%)4.05%
Case Studies0 (0.00%)4.05%
Observational8 (0.03%)0.25%
Observational0 (0.00%)0.25%
Other28,366 (94.17%)84.16%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]